WO1995011700A1 - Submicron emulsions as vaccine adjuvants - Google Patents

Submicron emulsions as vaccine adjuvants Download PDF

Info

Publication number
WO1995011700A1
WO1995011700A1 PCT/US1993/010402 US9310402W WO9511700A1 WO 1995011700 A1 WO1995011700 A1 WO 1995011700A1 US 9310402 W US9310402 W US 9310402W WO 9511700 A1 WO9511700 A1 WO 9511700A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
composition
emulsion
oil
immunogen
sme
Prior art date
Application number
PCT/US1993/010402
Other languages
French (fr)
Inventor
George H. Lowell
Shimon Amselem
Doron Friedman
Haim Aviv
Original Assignee
Pharmos Corp.
United States Of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • A61K39/008Leishmania antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/543Mucosal route intranasal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55544Bacterial toxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse Transcribing RNA Viruses
    • C12N2740/00011Reverse Transcribing RNA Viruses
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/409Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Leishmania i.e. Leishmaniasis, Sand-fly fever, phlebotomus fever, kala-azar, black fever or Dumdum fever
    • Y02A50/41Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Leishmania i.e. Leishmaniasis, Sand-fly fever, phlebotomus fever, kala-azar, black fever or Dumdum fever the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera

Abstract

A vaccine adjuvant composition of an oil-in-water submicron emulsion that has about 0.5 to 50 % of a first component of an oil, about 0.1 to 10 % of a second component of an emulsifier, about 0.05 to 5 % of a nonionic surfactant, about 0.00001 to 1 % of an immunogen, and an aqueous continuous phase. This submicron emulsion has a mean droplet size in the range of between about 0.03 and 0.5 νm, and preferably 0.05 and 0.2 νm.

Description

SUBMICRON EMULSIONS AS VACCINE ADJUVANTS

FIELD OF THE INVENTION

This invention relates to the use of oil-in-water submicron emulsions as vaccine adjuvants for enhancing the immunogenicity and improvement of the immune response of antigens and to methods and compositions for preparing them.

BACKGROUND OF THE INVENTION

In the past, the risks of whole-pathogen vaccines and limited supplies of useful antigens posed barriers to development of practical vaccines. Today, the tremendous advances of genetic engineering and the ability to obtain many synthetic recombinant protein antigens derived from parasites, viruses, and bacteria has revolutionized the development of new generation vaccines.

Although the new, small synthetic antigens offer advantages in the selection of antigenic epitopes and safety, a general drawback of small antigens is poor immunogenicity, resulting in low antibody titers and the need for repeated immunizations. This lack of immunogenicity has created an acute need to identify pharmaceutically acceptable delivery systems or adjuvants for these new antigens.

To improve the immune response usually antigens are mixed with adjuvant substances that stimulate immunogenicity. Immunological adjuvants have generally been divided into two basic types: aluminum salts and oil emulsions.

Aluminum phosphate and hydroxide (alum) have a long history of use as adjuvants. They are the only ones recognized as safe for this use by the Food and Drug Administration. Antibody levels against antigens in alum-based vaccines are clearly, although moderately, elevated above those obtained with the corresponding aqueous vaccine. However, aluminum compounds have not always enhanced the immunogenicity of vaccines, and the problem of inconsistent antibody production has been frequently cited. Occasional production of sterile abscesses and persistent nodules were also reported with alum-adjuvanted vaccines. Regarding long term side effects, researchers have suggested a link between aluminum and diseases of the brain, including Alzheimer's disease (Edelman, R. : Vaccine adjuvants. Rev. Inf. Dis. 1980; 2:370-383) .

The development of emulsified oil adjuvants emerged historically from the studies of J. Freund who observed a remarkable increase in both the antibody and delayed hypersensitivity response to killed mycobacteria if the organisms were incorporated in paraffin oil. There are two types of Freund's mineral-oil adjuvants: Incomplete Freund's Adjuvant (IFA) , consisting of an approximately 50:50 water-in-oil emulsion, and complete Freund's adjuvant (CFA) , a similar preparation with inclusion of killed mycobacteria. The powerful antibody-stimulating effect of CFA has not been surpassed by any other adjuvant. However, because of severe pain, abscess formation, fever and granulomatous inflammation, CFA can be used only for experimental purposes and not in human or veterinary vaccines. The toxic reactions reported using mineral oil-adjuvanted vaccines were attributed to impurities in Arlacel A (principally mannide monooleate) , the emulsifying agent used in the preparations.

The use of IFA in humans has been limited to those clinical situations in which aqueous vaccines are relatively impotent and aluminum compounds have not provided enough adjuvant activity. J. Salk made practical the use of IFA in human vaccines by using a highly refined mineral oil and a purified Arlacel A emulsifier free of toxic substances injected intramuscularly in thousands of recipients. However, occasional failure of IFA vaccines reported in humans, and the discovery that Arlacel A was carcinogenic in mice, despite the absence of increased tumor formation in humans, has restricted the use of IFA vaccine formulations.

Since CFA was the first successful adjuvant, most investigators followed the example of CFA in assuming that substitutes for each of the three components, viz. oil, emulsifier and i munostimulant, are necessary for formulating a successful adjuvant.

U.S. Patents 4,772,466 and 4,606,918 disclose methods for enhancing the immunogenicity of an antigen by emulsifying it with a polyoxypropylene-polyoxyethylene block polymer, a glycol ether-based surfactant, a metabolizable non-toxic oil, and an immunopotentiating amount of an immunostimulating glycopeptide.

Pharmaceutical compositions comprising an oil-in- water micron size emulsion, refined detoxified endotoxin, cell wall skeleton and trehalose dimycolate have been disclosed as vaccine adjuvants in U.S Patents 4,505,900 and 4,803,070.

International patent application (PCT) WO 90/14837 discloses adjuvant composition comprising a metabolizable oil and emulsifying agent in the form of an oil-in-water emulsion, where the antigen is added externally to the prepared emulsion (extrinsic formulation) . All the examples in the disclosure contained the immunostimulating agent, MTP-PE, a lipophilic muramyl peptide derivative.

SUMMARY OF INVENTION

The present invention provides vaccine adjuvant compositions in the form of an emulsion of a plurality of submicron oil-in-water droplets having a particle size in the range of between about 30 nm to about 500 nm to effect enhanced immunogenicity of antigens incorporated intrinsically or extrinsically into the droplets. These droplets or particles form a submicron emulsion ("SME") for use as the vaccine adjuvant.

In marked contrast to the aforementioned disclosures, as will be described, the present invention does not require use of any immunostimulatory mycobacteria or muramyl peptide-like additives for its submicron emulsion to be effective. Moreover, as will be seen, a preferred embodiment of the present invention consists of intrinsically incorporating the antigen into the emulsion at the time of formation of the emulsion; this is in distinct contrast to mixing the antigen with the emulsion after the emulsion has been independently extrinsically formed. It will be appreciated that intrinsic formulation will be effective even in situations and conditions and species where extrinsic formulation is not. In this regard as well, the present invention is uniquely different and not at all implied by the previously mentioned applications which indeed teaches away from the present invention in stating that it is sufficient to simply mix the antigen with the extrinsically previously formed emulsion.

The vaccine compositions of this invention also do not include any polyoxypropylene-polyoxyethylene block polymer, trehalose dimycolate, or cell wall skeleton, as are found in prior art compositions.

Another aspect of this invention is to provide compositions and methods for the preparation of submicron emulsions containing antigens, incorporated either intrinsically (emulsified together with the oil and surfactant) or extrinsically (added externally to a prepared SME) .

In some cases, the submicron emulsion of the present invention can be administered in combination with other adjuvant systems, such as proteosomes, as indicated in the examples. - 5 -

The size, concentration and specific formulation of SMEs may be varied to suit the particular antigen used. Moreover, such adjuvant preparations may enhance both humoral and cell-mediated immunity (CMI) as do Freund's adjuvants. The SMEs here described have been developed for human use and since the oily droplets of the emulsions are of submicron size and contain no added pyrogenic moieties such as mycobacteria or MDP derivatives they have, unlike Freund's adjuvants, great safety potential. They may be especially applicable to antigens that are vaccine candidates to protect against biologic toxins or infectious agents, which have natural hydrophobic moieties as a component including transmembrane viral, bacterial or parasite proteins, membrane proteins such as proteosomes, lipopolysaccharides, glycolipids such as gangliosides, or a variety of proteins or peptides to which hydrophobic anchors have been chemically or genetically added. Another aspect of the invention provides compositions and methods to achieve mucosal immunity by using an emulsion comprising a plurality of submicron particles, a mucoadhesive macromolecule, immunogenic peptide or antigen, and an aqueous continuous phase, which induces mucosal immunity by achieving mucoadhesion of the emulsion particles to mucosal surfaces. Mucous surfaces suitable for application of the emulsions of the present invention may include-ocular (cσrneal, conjunctival) , oral (buccal, sublingual) , nasal, vaginal and rectal routes of administration. The emulsion particles have a hydrophobic core comprising a lipid or lipid-like composition and are stabilized with amphiphilic and/or non-ionic surfactants. A wide variety of immunogens, including both water- soluble and water-insoluble peptides or polysaccharides, may be accommodated in the present emulsions. The hydrophobic core and surfactant provide a - 6 -

microenvironment which accommodates lipophilic immunogens such as lipid A or lipopolysaccharides as well as membrane-associated peptide antigen domains, while the aqueous continuous phase accommodates water-soluble peptide domains, or oligosaccharides.

The term "peptide" herein includes both oligopeptides and proteins. To facilitate intestinal uptake, the emulsions may be encapsulated in gelatin capsules or otherwise enterocoated to prevent their exposure to gastric fluids when the oral route of administration is selected. Furthermore, the emulsions may be lyophilized as disclosed previously in Pharmos Corp. International Application Publication WO 93/15736 prior to their encapsulation in order to achieve added stability of the antigen.

BRIEF DESCRIPTION OF THE DRAWING FIGURES

Figure 1 is a graph showing the size distribution of Intrinsic-SME vaccine containing SEB-Toxoid F antigen. Figures 2A and 2B show the immune response obtained after parenteral immunization with formalinized SEB- Toxoid (Toxoid F) at two different antigen doses, 10 μg (A) and 50 μg (B) , formulated in extrinsic-SME, intrinsic-SME, alum, or free antigen. Figure 3 shows the immunogenicity of SEB-Toxoid F complexed to proteosomes as a free antigen or adjuvanted with alum or extrinsic SME.

Figure 4 shows the anti gpl60 IgG antibody rabbit titers obtained after parenteral immunization with gpl60 formulated in alum, proteosomes or SME adjuvants.

Figure 5 shows the specific anti-Alex 10 (V3 loop) rabbit IgG titers obtained after parenteral immunization with gpl60 formulated in alum, proteosomes or SME adjuvants. DETAILED DESCRIPTION OF THE INVENTION

This invention is directed to pharmaceutical compositions comprising submicron emulsions as vaccine adjuvants, and to methods for preparing and using such compositions.

Features of the Submicron Emulsion (SME) Particles

The submicron emulsion vaccine adjuvants of the present invention comprise an aqueous continuous phase suspending a colloidal phase of submicron particles. The particles have a weighted average diameter of about 30 to 500 nm, more preferably about 50 to 200 nm. In many embodiments, the weighted average diameter be less than 460 nm, 400 nm, 300 nm, or 200 nm. Usually the weighted average diameter will be greater than 40 nm or 50 nm, and frequently is greater than 70 nm. Often, the above-stated upper and lower diameter ranges will include both the weighted average and at least one standard deviation of particle diameter. The emulsion particle comprises a hydrophobic core, often including or even consisting essentially of a metabolizable and non-toxic oil such as MCT (medium chain triglycerides) oil of the type extensively used in parenteral emulsions like INTRALIPID® or a vegetable oil. Optionally, other hydrophobic lipids may be used, including cholesterol or cholesteryl esters and fatty acids. In many embodiments, the core of the particles will be substantially free of protein other than the antigen to be delivered, i.e. less than 1% (w/w) , and in most cases less than 0.1% of other protein.

The emulsion usually further includes at least one surfactant, which may be a natural biologically compatible surfactant such as phospholipid (e.g., lecithin) or a pharmaceutically acceptable non-natural surfactant such as TWEEN-80. The surfactant assists in - 8 -

maintaining particles within the desired size range and preventing their aggregation.

In many embodiments the emulsion may be formed and stabilized in the substantial absence of one or more cosurfactants selected from the group consisting of an unhalogenated aliphatic C3-C6 alcohol, a free fatty acid, a mono- or di-glyceride, a polyglycerol fatty acid ester, or a lysophosphatidyl choline. One or all of the above- named cosurfactants may comprise less than 5%, commonly less than 1%, and frequently less than 0.1% (w/w) relative to the weight of the hydrophobic core.

The emulsion also contains an immunogen, preferably of an antigen. The antigen may be hydrophilic, hydrophobic, or amphiphilic since the emulsion provides a biphasic lipophilic-hydrophilic microenvironment.

The continuous phase of the emulsion is aqueous, and may contain salts, sugars, antioxidants, preservatives, microbicides, buffers, osmoticants, cryoprotectants, and other pharmaceutically useful additives or solutes. Bioadhesive polymers, such as those currently used in pharmaceutical preparations, optionally may be added to the emulsion to further enhance the immunogenicity through mucous membranes achieving mucosal immunity.

The concentrations indicated by % in the following description denote the concentration by weight of the component per 100 units volume of the entire composition. Also, all indicated concentrations should be understood as standing each by itself, and not cumulative. It should be appreciated by the artisan, however, that there is some dependency between the concentrations of the components, e.g., higher concentrations of the oil will generally require higher concentrations of the emulsifier and surfactant.

The emulsion used in the vaccine compositions of the present invention typically contain about 0.5 to 50% oil, about 0.1 to 10% emulsifier and about 0.05 to 5% of the non-aqueous phase. The combined concentration of the oily and the amphiphilic phase increases viscosity of the composition. In order to obtain a non-viscous composition, the concentration of the non-aqueous phase should generally not exceed about 25%.

Preferred concentrations of the components are as follows: about 1 to 20% oil, most preferably about 1 to 10% for a composition intended to be fluid, about 0.2 to 5% of the emulsifier, with about 0.2 to 5% for the surfactant, with about 0.1 to 2% being particularly preferred.

The antigen is present in an amount of about 0.00001 to 1% by weight of the composition, preferably about 0.0001 to 0.5% and most preferably 0.001 to 0.1%. Depending upon whether the antigen is hydrophilic or hydrophobic, it will be physically present in the oily phase at the oil-water interface, or the aqueous component. Also, the pH of these compositions should be in a range which is suitable for the stability of the antigen.

The submicron emulsion adjuvant formulations of this invention differ from the emulsion adjuvant composition of Patent Application WO 90/14837 in the following features: (i) all the compositions described in the abovementioned application are prepared extrinsically, namely the antigens are added externally to the previously prepared emulsion by mixing, while in the present invention the antigen can be added either extrinsically or more preferably intrinsically, together with all the emulsion components before emulsification and prior to the mixture of oil and water phases as detailed in the examples; and (ii) all the examples in the abovementioned disclosure contain an immunopotentiating amount of an immune-stimulating glycopeptide of the type of mura yl peptides or their lipophilic derivatives, such as MTP-PE, while in the present invention all the SME adjuvant compositions are prepared in the absence of any muramyl peptide immunostimulating agent.

Composition of the Hydrophobic Core

A hydrophobic compound which is suitably non-toxic may be used as a component of the core. Examples include triglycerides, preferably of food grade purity or better, which may be produced by synthesis or by isolation from natural sources. Natural sources may include animal fat or vegetable oil, e.g., soya oil, a source of long chain triglycerides (LCT) . Other triglycerides of interest are composed predominantly of medium length fatty acids, denoted medium chain triglycerides (MCT) . A medium chain triglyceride (MCT) oil, is a triglyceride in which the carbohydrate chain has 8-12 carbons. Although MCT oil can be considered as a component of vegetable oil, it is separately identified herein because of its particular utility as a preferred oil for use in the present emulsions. In addition, MCT oil is available commercially. Examples of such MCT oils include TCR (trade name of Societe Industrielle des Oleagineuax, France, for a mixture of triglycerides wherein about 95% of the fatty acid chains have 8 or 10 carbons) and MIGLYOL 812 (trade name of Dynamit Nobel, Sweden for a mixed triester of glycerine and of caprylic and capric acids) . The fatty acid moieties of such triglycerides may be unsaturated, monounsaturated or polyunsaturated; mixtures of triglycerides having various fatty acid moieties are acceptable. The core may comprise a single hydrophobic compound or a mixture of compounds.

Examples of vegetable oils include soybean oil, cotton seed oil, olive oil, sesame oil and castor oil. Oily fatty acids, such as oleic acid and linoleic acid, fatty alcohols, such as oleyl alcohol, and fatty esters, such as sorbitan monooleate and sucrose mono-, di- or tripalmitate, can be used as the oil component, although these are not as preferred as the other oils mentioned above.

Optionally, the core may contain cholesterol or cholesteryl esters. In many embodiments, cholesteryl esters or cholesterol comprise less than 10%, 5%, 1%, or even 0.1% (w/w) of the total hydrophobic components of the core. Considerations in choice of core material include low toxicity and irritancy, biocompatibility, safety, metabolizability, stability and high loading capacity for antigens. Preferred hydrophobic core components have molecular weights below about 5,000 Da, more preferably below about 2,000 Da, and most preferably below about 1,500 Da.

Composition of Surfactant Component

The amphiphilic phase comprises the emulsifiers and surfactants. Preferred emulsifiers include a phospholipid compound or a mixture of phospholipids. Suitable components include lecithin; EPICURON 120 (Lucas Meyer, Germany) which is a mixture of about 70% of phosphatidylcholine, 12% phosphatidylethanolamine and about 15% other phospholipids; OVOTHIN 160 (Lucas Meyer, Germany) which is a mixture comprising about 60% phosphatidylcholine, 18% phosphatidylethanolamine and 12% other phospholipids; a purified phospholipid mixture- LIPOID E-75 or LIPOID E-80 (Lipoid, Germany) which is a phospholipid mixture comprising about 80% phosphatidylcholine, 8% phosphatidylethanolamine, 3.6% non-polar lipids and about 2% sphingomyelin. Purified egg yolk phospholipids, soybean oil phospholipids or other purified phospholipid mixtures are useful as this component. This listing is representative and not - 12 -

limiting, as other phospholipid materials which are known to those skilled in the art can be used.

Some embodiments of the invention provide an improved bioadhesive emulsion comprising incorporation of an amphiphilic and/or nonionic surfactant such as phosphatidylcholine, Tween, etc., together with a mucoadhesive polymer macromolecule as described below.

Particularly suitable emulsifiers include phospholipids, which are highly biocompatible. Especially preferable phospholipids are phosphatidylcholines (lecithins) , such as soy or egg lecithin. Other suitable phospholipids include phosphatidylglycerol, phosphatidylinositol, phosphatidylserine, phosphatidic acid, cardiolipin, and phosphatidylethanolamine. The phospholipids may be isolated from natural sources or prepared by synthesis. Phospholipid surfactants are believed usually to form a single monolayer coating of the hydrophobic core.

The surfactant is believed in many embodiments to interact with the bioadhesive polymer to form a hydrated polymer film coating associated with the surfactant at the stabilized lipid/water interface surrounding the particle core.

Preferred compositions contain a surfactant component. The surfactant stabilizes the outer surface of the hydrophobic core component of the emulsion particles, thereby promoting a more uniform and manipulatable particle size. Usually the surfactant is present in a proportion of 0.01% to 5% (w/w) of the emulsion, preferably 0.05% to 2% and most preferably 0.1 to 2%.

Typically, the weight percentage of surfactant relative to hydrophobic (oil or other lipid) component is from 0.2% to 50%, more preferably from 5% to 20%. Higher ratios of surfactant to core lipid tend to promote smaller particle core diameters. - 13 -

Surfactants may be either natural compounds, such as phospholipids and cholates, or non-natural compounds such as: polysorbates, which are fatty acid esters of polyethoxylated sorbitol (TWEEN) ; polyethylene glycol esters of fatty acids from sources such as castor oil

(EMULFOR) ; polyethoxylated fatty acid, e.g., stearic acid (SIMULSOL M-53); NONIDET; polyethoxylated isooctylphenol/formaldehyde polymer (TYLOXAPOL) ; polyoxyethylene fatty alcohol ethers (BRIJ) ; polyoxy- ethylene nonphenyl ethers (TRITON N) ; polyoxyethylene iεooctylphenyl ethers (TRITON X) . Mixtures of surfactant molecules, including mixtures of surfactants of different chemical types, are acceptable. Surfactants should be suitable for pharmaceutical administration and compatible with the peptide to be delivered.

In certain embodiments, the emulsion may be limited in or substantially free of one or more cosurfactants selected from the group consisting of free fatty acids, mono- or diglycerides (fatty acid mono- or diesters of glycerol) , aliphatic C3-C6 monoalcohols (exclusive of, , e.g., chlorobutanol or other haloalkyl alcohol preservative) , polyglycerol fatty acid esters, or lysophosphatidyl choline. In many embodiments, the particular limited cosurfactant from the above group may constitute less than 5%, usually less than 1%, often less than 0.1%, relative to the weight of hydrophobic core component. In some embodiments, one or more cosurfactants may be present.

Continuous Aqueous Phase

The aqueous component will be the continuous phase of the emulsion and may be water, saline or any other suitable aqueous solution which can yield an isotonic and pH controlled preparation. In addition, the compositions of the invention may also comprise conventional additives such as preservatives, osmotic agents or pressure regulators and antioxidants. Typical preservatives include Thimerosal, chlorbutanol, and methyl, ethyl, propyl or butyl parabens. Typical osmotic pressure regulators include glycerol and mannitol, with glycerol being preferred.

The preferred oil phase antioxidant is α-tocopherol or α- tocopherol succinate. The aqueous phase may also include an antioxidant of a polyamine carboxylic acid such as ethylene diamino tetraacetic acid, or a pharmaceutically acceptable salt thereof.

Antigens

Since the SME particles provide a hydrophilic- lipophilic microenvironment, either water-soluble or lipid-soluble immunogens can be incorporated in the SME vaccines of the present invention. Examples of peptide antigens are: hydrophilic natural or synthetic peptides and proteins derived from bacteria, viruses and parasites, such as the recombinant gpl60 envelope protein of the HIV virus; natural or synthetic glycoproteins derived from parasites, bacteria or viruses such as the native surface glycoprotein of Leiεhmania strain or subunit vaccines containing part of the glycopeptides alone or covalently conjugated to lipopeptides like lauryl-cystein hydrophobic foot; protein toxoids such as the Staphylococcus enterotoxin B toxoid, either chemically or physically inactivated, non-toxic bacterial surface structures (fimbrial adhesions) of Eεchesichia coli strains such as the Shiga-like Toxin B Subunit (SLT- B) and AF-RL, a pilus adhesion which is a virulence factor for RDEC-l E. coli strain; outer membrane proteins of Neisεeria meningitides; Hepatitis B surface antigen; native or synthetic malaria antigens derived from different portions of Plaεmodium falciparum, etc . Examples of lipophilic or hydrophobic immunogens are lipopolysaccharides (LPS) , such as detoxified LPS obtained from E. coli (Sigma Chemical Co., St. Louis, USA) ; Lipid A, the terminal portion of LPS, such as the one isolated from Salmonella minnesota R595 from List Biological Laboratories (CA, USA) .

In some embodiments, the emulsion particles will be free or substantially free of the above or other nonbioactive proteins, i.e. less than 5%, usually less than 1%, and frequently less than 0.1% (w/w) protein relative to other particle components.

Bioadhesive SME Vaccine Adjuvants

Submicron emulsion vaccine adjuvants of the present invention optionally may contain a bioadhesive macromolecule or polymer in an amount sufficient to confer bioadhesive properties. The bioadhesive macromolecule enhances the delivery and attachment of antigens on or through the target mucous surface conferring mucosal immunity. The bioadhesive macromolecule may be selected from acidic non-naturally occurring polymers, preferably having at least one acidic group per four repeating or monomeric subunit moieties, such as polyacrylic acid and/or polymethacrylic acid (e.g. CARBOPOL, CARBOMER) , poly( ethylvinyl ether/maleic anhydride) copolymer, and their mixtures and copolymers; acidic synthetically modified natural polymers, such as carboxymethylcellulose (CMC) ; neutral synthetically modified natural polymers, such as (hydroxypropyl) methylcellulose; basic amine-bearing polymers such as chitosan; acidic polymers obtainable from natural sources, such as alginic acid, hyaluronic acid, pectin, gum tragacanth, and karaya gum; and neutral non-naturally occurring polymers, such as polyvinylalcohol; or their mixtures.

The ionizable polymers may be present as free acids, bases, or salts, usually in a final concentration of 0.01-0.5% (w/v) . As used herein, a polymer of an indicated monomeric subunit contains at least 75%, preferably at least 90%, and up to 100% of the indicated type of monomer subunit; a copolymer of an indicated type of monomeric subunit contains at least 10%, preferably at least 25% of that monomeric subunit.

A preferred bioadhesive macromolecule is the family of acrylic acid polymers and copolymers (e.g. CARBOPOL™) . These contain the general structure:

-[-CH2-CH(COOH)-]-n

One preferred group of polymers of acrylic acid is commercially available under the tradename CARBOPOL. CARBOPOL 934 is available in a pharmaceutical grade.

Preferred bioadhesive or mucoadhesive macromolecules have a molecular weight of at least SO'kDa, preferably at least 300 kDa, and most preferably at least 1,000 kDa. Favored polymeric ionizable mucoadhesive macromolecules have not less than 2 mole percent acidic groups (e.g. COOH, S03H) or basic groups (NH2, NRH, NR2) , relative to the number of monomeric units. More preferably, the acidic or basic groups constitute at least 5 mole percent, more preferably 25 or even 50, up to 100 mole % relative to the number of monomeric units of the macromolecule.

Preferred macromolecules also are soluble in water throughout their relevant concentration range (0.01-0.5% w/v) .

Methods of Preparation

A further embodiment of the invention relates to methods for preparation of submicron emulsion vaccine adjuvants intrinsically and extrinsically as extensively detailed in the examples. In general, SME intrinsic formulations are prepared by emulsifying the antigen together with the SME components, while SME extrinsic formulations are prepared by adding externally the antigen to previously prepared plain SME.

Dehydrated SME Adjuvants

A further aspect of the invention provides dehydrated emulsions, made by dehydrating the submicron emulsion of the types described herein. Dehydrated submicron emulsions may be stored for prolonged periods with minimal degradation, then reconstituted with water shortly before use. Residual water content in the dehydrated emulsion is usually less than 5% (w/w) , commonly less than 2%, and often less than 1%.

Dehydration may be performed by standard methods, such as drying under reduced pressure; when the emulsion is frozen prior to dehydration, this low pressure evaporation is known as lyophilization. Freezing may be performed conveniently in a dry ice-acetone or ethyl alcohol bath. The pressure reduction may be achieved conveniently with a mechanical vacuum pump, usually fitted with a liquid nitrogen cold trap to protect the pump from contamination. Pressures in the low millitorr range, e.g., 10-50 millitorr, are routinely achievable but higher or lower pressures are sufficient. A cryoprotectant or anticoalescent compound may be added to the emulsion prior to dehydration to inhibit flocculation and coalescence upon rehydration. The cryoprotectant may be of any type known in the art, including sugars and polysaccharides such as sucrose or trehalose, and non-natural polymers such as polyvinylpyrrolidone. Cryoprotectants are usually present at less than 25%, commonly 10%, more commonly 5%, 4% (w/v) or less in the emulsion before lyophilization. A preferred category of cryoprotectants is amino acids and oligopeptides. Preferred amino acids include valine, leucine, isoleucine, lysine, methionine. threonine, serine, arginine, alanine, glycine, histidine, proline, phenylalanine, taurine, and carnitine, although any of the other natural amino acids may also be present. Amino acids may be of either D or L configuration, or a mixture; the natural L form is preferred. Amino acids may be present as their salts or esters, and as mixtures of amino acids or as pure species.

A particularly preferred amino acid is glycine, which may be present either in pure form or as a component of a mixture, e.g. in an hydrolyzate of collagen or other glycine-rich protein.

Mixtures of oligopeptides, especially di- and tripeptides, are another preferred type of cryoprotectant. These may be prepared conveniently as partial protein hydrolysates or enzymatic digests.

The cryoprotective amino acids or oligopeptides are generally present in the emulsion at a concentration of about 0.25 to 25% (w/w) , preferably about 0.5 to 12% (w/w) , more preferably about 1 to 10% (w/w) and commonly 3-6% (w/w) .

Cryoprotectants and methods of making lyophilized submicron emulsions are taught in more detail in Pharmos Corp. PCT International Application Publication WO 93/15736 entitled "Dry Compositions for Preparing Submicron Emulsions", the content of which is expressly incorporated herein by reference.

EXAMPLES

This invention is illustrated by the following non- limiting examples:

Example 1: Preparation of Intrinsic-gplβO-SME vaccine

Antigen description and background. The urgency and high priority for developing an effective vaccine against the human immunodeficiency virus (HIV) are fully recognized. The reasons for using subunits of the virus as the basis of an HIV vaccine are the perceived overwhelming requirements for safety. Despite the high efficacy of many live attenuated viral vaccines, the requirement for product safety, especially in the case of retroviruses, has favored the subunit approach to the extent that all of the current candidate preparations in clinical prophylactic trials are of this type, being mainly gpl60, the envelope protein of HIV, or part thereof. Studies have shown that gpl60 attaches the virus to the cell and also facilitates the fusion of the cell and virus during the early stages of infection.

The gpl60 antigen used in this example was supplied by MicroGeneSys Inc. This gpi60 recombinant protein in alu -adjuvanted vaccine formulation is currently under evaluation in human clinical trials.

Preparation of oil phase

The oil phase was composed of MCT oil (2.0 g Mygliol 812, Hulls, Germany), lecithin (0.4 g, Lipoid E-80, Germany), and DL-α-tocopherol succinate (8.0 g, Merck, Germany). The lipids and oil were weighed in a 250-ml beaker and mixed at room temperature using a magnetic stirrer during 2-4 hrs until a homogenous and almost clear solution was obtained.

Preparation of water phase

Polysorbate 80 (1 % w/v, Montanox 80, DF, Seppic,

France), Glycerol (2.2% w/v, Merck, Germany), EDTA (0. 1 % w/v, Merck, Germany) , and purified water (to 100% w/v) were dissolved at room temperature in a 250-ml beaker by gentle shaking using a magnetic stirrer plate until a clear homogenous solution was obtained (about 15-20 in) . A total volume of 40 ml of water phase was prepared. A vial containing 2.1 ml of gpl60 recombinant protein

(MicroGeneSys, Inc., CT, USA) at a concentration of 0.25 - 20 -

mg/ml in saline was added to the water phase and the mixture was gently shaken for 5 min.

Mixing of oil and water phase The oil phase was heated to 40°C and added to the beaker containing the 40 ml of water phase. The mixture was gently stirred for 10-15 min at room temperature.

Preparation of oil-in-water coarse emulsion An oil-in-water emulsion containing the antigen was prepared using the medium-sized disperser and homogenizing unit Polytron PT3000 (Kinematics, Switzerland) at 3,600 rpm for 30 sec. The resultant micronsize emulsion was cooled at room temperature.

Sizing of emulsion to submicron range

The droplet size of the emulsion obtained after Polytron step was lowered to the submicron (nanosize) range by submitting the emulsion to high shear homogenization using the Gaulin Microlab 70 High Pressure Homogenizer

(APV Gaulin, Germany) at 800 bar pressure. A total of 10 cycles were performed. The particle size distribution of the resultant formulation was determined using an N4MD Coulter Particle Size Analyzer (Coulter Electronics, England) . The differential weight % mode of the instrument indicated the existence of homogeneous population of SME droplets with a mean particle size distribution of 43±35 nm. The estimated final gpl60 concentration in the formulation was 56 μg/ml.

Example 2: Preparation of Intrinsic-SME vaccine containing gplβo complexed to proteosomes

Proteosomes are meningococcal outer membrane protein preparations purified from Neisεeria meningitidiε by detergent extraction and ammonium sulphate precipitation. - 21 -

They naturally form 20-100 nm diameter hydrophobic membraneous vesicles. Antigens are non-covalently complexed to proteosomes via hydrophobic interactions by mixing the antigen and proteosomes in the presence of detergent and then removing the detergent over a prescribed period of time, permitting hydrophobic interactions to occur in the system.

Proteosomes have previously been shown to enhance the parenteral immunogenicity of peptides, gangliosides, lipopolysaccharides and proteins hydrophobically complexed to them (Lowell, G.H., L.F. Smith, R.C. Seid and W.D. Zollinger, J. Exp. Med. 167: 658-663, 1988). (Lowell, G.H., W.R. Ballou, L.F. Smith, R.A. Wirtz, W.D. Zollinger and W.T. Hockmeyer. Science 240: 800-802, 1988; Lowell, G.H. 1990. In: New Generation Vaccines. G.C. Woodrow and M.M. Levine (eds.), Marcel Dekker, Inc., New York, p. 141-160) . and have been shown to be safe for human use in vaccine trials involving tens of thousands of humans in the development of anti-meningococcal vaccines (Zollinger, W.D. New and Improved Vaccines Against Meningococcal Disease. In: New Generation Vaccines, G.C. Woodrow and M.M. Levine (eds.). Marcel Dekker, Inc., New York, p. 325-348). Furthermore, proteosomes confer mucosal immunogenicity upon non- immunogenic antigens when administered orally or intranasally. Such intranasal or oral proteosome vaccines induce up to 100% protection against lethal pneumonia or keratoconjunctivitis in experimental murine models of shigellosis (Orr, N., G. Robin, D. Cohen, R. Arnon and G. Lowell. 1993. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella εonnei proteosome-lipopolysaccharide vaccines in animal models. Infect. Immun. 61: 2390-2395). Oil and aqueous phases were prepared as described in Example 1. A vial containing 2.5 mg of gpl60 non- covalently complexed to proteosomes and suspended in saline was added to the water phase (40 ml total volume) and the mixture was gently shaken for 5 min. The subsequent steps involved in the preparation of the SME, i.e. mixing of oil and water phases, homogenization and sizing to submicron range were carried out as described in Example 1. The particle size volume % distribution of the resultant formulation showed a mean droplet size of 38±41 nm. The estimated final gpl60 concentration in the formulation was 46 μg/ml.

Example 3: Preparation of Extrinsic-gpl60-SME vaccine

Extrinsic formulations of gpl60 in SME were performed by preparing plain SME as described in Example 1, but in the absence of the antigen and adding externally the aqueous solution containing the gpl60 to the plain SME by gently shaking for 15 min at room temperature. A total volume of 2.3 mi of plain SME (average droplet size of 50±36 nm) were mixed with 2.1 ml solution of gpl60 in saline containing 1.1 mg protein to give a final gpl60 concentration of 0.25 mg/ml.

Example 4: Preparation of Extrinsic-SME vaccine containing gpl60 complexed to proteosomes

Extrinsic formulation of gpl60 conjugated to proteosomes in SME were performed by preparing plain SME as described in Example 1 , but in the absence of the antigen and adding externally an aqueous dispersion of the gpl60- conjugated to proteosomes to the plain SME by gently shaking for 15 min at room temperature. A total volume of 5.4 ml of plain SME (average droplet size of 50±36 nm) were mixed with 7.0 ml saline containing 3.1 mg of gpl 60 complexed to proteosomes to give a final gpl60 concentration of 0.25 mg/ml.

Example 5: Preparation of Intrinsic-SME vaccine containing Staphylococcus Enterotoxin B Toxoid-F

Antigen description and background: Staphylococcal enterotoxin B (SEB) is a potent toxin that causes food borne illness among civilians and military personnel stationed around the world and is identified as a lethal offensive military threat that endangers both military and civilian populations through aerosolization.

SEB infection in civilian populations is related to staphylococcal food poisoning by SEB and related toxins: also contributes to death from staphylococcal sepsis following overwhelming staph infection. It also causes staph scalded skin syndrome in kids - i.e. morbidity and mortality from staphylococcal infections (P. Marrack and J. Kappler, Science, vol. 248, pp. 705-711.)

Due to the similarity to the human response both in sensitivity and clinical signs and the lack of an established model for lethality to SEB delivered via the respiratory route in lower animal species, non-human primates have been the primary animal model for development of vaccines to protect against respiratory challenge with SEB. Early work indicated that monkeys develop decreased sensitivity to repeated mucosal administration of the toxin. This suggested that protection to SEB exposure might be provided by toxoid immunization. Studies in rhesus monkeys and other animals indicated that oral immunization with formalinized toxoid was ineffective against parenteral challenge whereas parenteral immunization with formalinized SEB toxic induced serum antibodies that recognized native SEB (Bergdoll, M.S. Enterotoxins. pp. 559-598 In: Staphylococci and Staphylococcal Infections, eds. C.S.F. Easmon and C. Adlam, Academic Press, London, 1983) . In the latter studies, however, several parenterally immunized monkeys that acquired anti-SEB antibodies had severe immediate-type hypersensitivity reactions when challenged with SEB toxin. These adverse reactions suggested that the formalinized SEB toxoid alone was not a candidate for parenteral vaccine development. Additionally, as the military threat would be by aerosolization, it was determined that studies on protection provided by serum IgG to respiratory challenge as well as protective effects provided by anti-SEB secretory IgA in the respiratory tract were required.

Recently, two identical lots of formalinized SEB toxoid were made at Walter Reed Army Institute of Research, Washington DC (WRAIR) following previously described specifications (Kaminski, R. , S. Grate, E. Aboud-Pirak, C. Hooper, T. Levin, I. Weiss, S. Amselem, R. Arnon and G. Lowell, 1993) . Comparison of induction of respiratory IgA and serum lg by intranasal and parenteral proteosome vaccines formulated with staphylococcal enterotoxin B toxoids or ricin peptides. In Proceedings of 1993 Medical Defense Bioscience Review, Baltimore, Maryland) . This WRAIR formalinized toxoid preparation designated

Tox-F was non-toxic in rabbits at 0.5 mg/kg, the dose at which SEB toxin is invariably lethal. Furthermore, it was non-toxic in the murine D-galactosamine model of SEB toxicity even at 500 μg per BALB/C mouse; 50 μg of SEB is 100% lethal in such mice. The physical characteristics of Tox-F were similar to that described by Eldridge (Eldridge, J.H., Staas, J.K., Meulbroek, J.A. , Tice, T.T. and Gilley, R.M. Biodegradable and biocompatible poly(DL- lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect, lmmun. 59: 2978-2986, 1991) is that SDS-PAGE gel of Tox-F showed two distinct bands with estimated MW of 23,000 and 46,000. Biologically, Tox-F also had the characteristics previously reported by Eldridge et al . , namely in a Mouse Spleen Lymphocyte Proliferative Assay in which concentrations of SEB toxin of 0.37-10.0 μg/ml were mitogenic, Tox-F was entirely non-mitogenic at all concentrations tested (0.04-1 00.0 μg/ml).

Preparation of SEB- Toxoid F

Formalinized SEB-Toxoid (Tox-F) was prepared according to the method of Warren, J.R., Spero, L. and Metzger, J.F.

1983. J. Immunol. Ill: 885-892 and as per Eldridge, J.H. et al . 1991, Infect. Immun. 59: 2978-2986 by formalin treatment for 30 days at 37°C, pH 7.5.

Preparation of SME

Preparation of oil phaεe Oil phase was composed of MCT oil (0.77g, Mygliol 812, Hulls, Germany), lecithin (0.14 g, Lipoid E-80, Germany) and DL-α-tocopherol succinate (9.0 mg, Merck, Germany). The lipids and oil were weighed in a 250-ml beaker and mixed at room temperature using a magnetic stirrer during 2-4 hours until a homogenous and almost clear solution was obtained.

Preparation of water phaεe

Polysorbate 80 (0.5% w/v, Montanox 80, DF, Seppic, France), Glycerol (2.2% w/v, Merck, Germany), EDTA (0.1% w/v, Merck, Germany) , and purified water (to 100% w/v) were dissolved at room temperature in a 250-ml beaker by gently shaking using a magnetic stirrer plate until a clear homogenous solution was obtained (about 15-20 min) . A total volume of 45 ml of water phase was prepared. A vial containing 10 ml of SEB-Toxoid F in 6.3 ml buffer was added to the water phase and the mixture was gently shaken for 5 min.

Preparation of oil-in-water coarεe emulεion An oil-in-water emulsion containing the antigen was prepared by heating the oil phaεe to 40°C and mixing it with the water phase with the aid of a 10 ml glass pipette until a homogenous and milky dispersion was obtained. The resultant micronsize emulsion was cooled at room temperature.

Sizing of emulεion to εubmicron range

The droplet size of the emulsion obtained after the

Polytron step was lowered to submicron (nanosize) range by subjecting the emulsion to high shear homogenization using the Gaulin Microlab 70 High Pressure Homogenizer (APV Gaulin, Germany) at 800 bar pressure. A total of 5 cycles were performed. The particle size distribution of the resultant formulation was determined using an N4MD Coulter Particle Size Analyzer (Coulter Electronics, England) . The differential weight % mode of the instrument indicated the existence of a single and homogenous population of SME droplets with a mean particle size distribution of 47.5±58 nm (see Fig. 1) . The estimated final antigen concentration in the formulation was 220 μg/ml.

Example 6: Preparation of Extrinsic SME vaccine containing Staphylococcus Enterotoxin B Toxoid-F

Extrinsic formulations of SEB-Toxoid-F in SME were performed by preparing plain SME as described in Example

5, but in the absence of the antigen and adding externally the aqueous solution containing the SEB-

Toxoid-F to the plain SME by gently shaking for 15 min at room temperature. A total volume of 0.780 ml of stock SME were mixed with 0.780 ml solution of SEB-Toxoid-Fin 0.01 M Triε 0.15M NaCl buffer containing 0.780 mg protein to give a final SEB-Toxoid-F concentration of 0.500 mg/ml.

Example 7: Preparation of Extrinsic SME vaccine containing Staphylococcus Enterotoxin B Toxoid F complexed to proteosomes

Extrinsic formulations of SEB-Toxoid-F in SME were performed by preparing plain SME as described in Example 5, but in the absence of the antigen and adding externally the aqueous solution containing the SEB- Toxoid-F complexed to proteosomes to the plain SME by gently shaking for 15 min at room temperature. A total volume of 0.780 ml of stock SME were mixed with 0.780 ml solution of SEB-Toxoid-F complexed to proteosomes in 0.01 M Tris 0.15M NaCl buffer containing 0.780 mg protein to give a final SEB-Toxoid-F concentration of 0.500 mg/ml.

Example 8: Preparation of Extrinsic-SME vaccine containing Staphylococcus Enterotoxin B

Toxoid C

Preparation of SEB-Toxoid-C

Carboxymethylated Toxoid (Tox-C) : Carboxymethylated with

0.4 Bro oacetic Acid, pH 7.0 for 11 or 21 days in the dark at 20°C as per Sterna, G.N. and Bergdoll, M.S. 1982.

Biophys. Biochem. Reε. Commun. 105: 121-126 and aε per

Scheuber et al . 1985. Infect. Immunol. 50: 869-876.

Made at WRAIR according to deεcribed methods.

Extrinsic formulations of SEB-Toxoid-C in SME were performed by preparing plain SME as described in Example 5, but in the absence of the antigen and adding externally the aqueous solution containing the SEB- Toxoid-C to the plain SME by gently shaking for 15 min at room temperature. A total volume of 0.165 ml of stock SME were mixed with 0.110 ml solution of SEB-Toxoid-C in - 28 -

water containing 0.110 mg protein to give a final SEB- Toxoid-C concentration of 0.400 mg/ml.

Example 9: Preparation of Extrinsic SME vaccine containing Staphylococcus Enterotoxin B Toxoid-C complexed to proteosomes

Extrinsic formulations of SEB-Toxoid-C in SME were performed by preparing plain SME as described in Example 5, but in the absence of the antigen and adding externally the aqueous solution containing the SEB- Toxoid-C complexed to proteosomeε to the plain SME by gentle εhaking for 15 min at room temperature. A total volume of 0.045 ml of stock SME were mixed with 0.230 ml solution of SEB-Toxoid-C complexed to proteosomes in water containing 0.110 mg protein to give a final SEB- Toxoid-C concentration of 0.400 mg/ml.

Example 10: Preparation of Mucoadhesive Extrinsic SME

Formulation containing 0.05% Carbopol

420 ml of distilled water in which were dissolved 0.250 g Carbopol-940 (Goodrich, U.S.) and 11.2 g glycerol

(isotonic agent), pH 3.82, were warmed to 45°C and mixed with the oil phase, conεiεting of 21.2 g MCT oil (medium chain triglycerideε, SIO, France), 3.74 g Lipoid E-75

(egg lecithin) and 1.5% w/v Emulfor EL-620 (Rhone- Poulenc, France) , at a temperature of 60°C. After mixing by high εpeed εtirrer (Polytron 3000, Kinematica,

Switzerland) at 20,000 rpm for 5 minutes the mixture was dispersed by a high presεure homogenizer (Gaulin Microlab

70) at 700 bar for 5 minuteε (approximately 10 cycleε) . The reεulting emulsion was cooled, and after adjusting the pH to 5.0, the emulsion was filtered and packed in sterile bottles through a 0.2 μm filter.

After filtering, droplet size waε meaεured by the photon correlation spectroscopy using a particle size analyzer (N4MD, Coulter Electronics, U.S.A.). The droplet size for carbopol containing droplets was 127±79 nm. This mucoadhesive composition was prepared as an extrinsic plain SME formulation to be added to the specific immunogen by gentle mixing.

Example ll: Enhanced Immunogencity to SEB Antigen after Parenteral immunization with Intrinsic and Extrinsic SEB-Toxoid F-SME Vaccines compared to Free Antigen or Alum- Adjuvanted Vaccine

The antigen used was Staphylococcal Enterotoxin B (SEB) toxoid F alone or SEB toxoid complexed to meningococcal outer membrane proteosomes. This antigen waε formulated with SME adjuvant either intrinεically or extrinεically, as described in Examples 5, 6 and 7, and compared to SEB toxoid-F alone or adjuvanted with alum. Outbred CD-I mice, 5 animals/group, were immunized twice at approximately 3 week intervalε by intramuεcular injectionε with 10 or 50 μg doεeε of SEB Toxoid F. Sera, obtained after firεt and second immunizations, were analyzed by ELISA techniques using anti-SEB aε the detecting antibody. Aε εhown in Figureε 2 and 3, intrinεic and extrinsic-SME formulationε with (Fig. 2) or without proteosomes (Fig. 3) were effective in enhancing immunity to SEB antigens. In all the cases, the anti-SEB serum IgG titers obtained with the SME-adjuvant were several orders of magnitude higher than those obtained with the alum-adjuvanted formulation.

Example 12: Enhanced Immunogenicity to SEB Antigen after Parenteral Immunization with SEB- Toxoid-C SME Vaccines compared to Free Antigen or Alum-Adjuvanted Vaccine.

The antigen uεed waε carboxymethylated SEB-Toxoid or

Toxoid-C. The antigen waε incorporated extrinεically in

SME, aε described in Example 9. The immunization protocol and sera analysis for antibody activity was aε - 30 -

described in Example 11. Mice were immunized intramuεcularly with two lOμg doεeε of Toxoid-C. Aε εhown in Table 1, parenteral immunization with Toxoid-C- SME vaccine induced a 4-fold increaεe in the level of serum IgG even in the absence of proteosomeε.

TABLE l. Effects of formulation with saline, alum or submicron emulsion (SME) on parenteral (intramuscular) immunogenicity of carboxymethylated SEB toxoid (Toxoid-C)

Figure imgf000032_0001

Example 13: Intranasal Immunization with SEB-Toxoid F SME Vaccines

Immunization against biologic threat agentε, εuch aε SEB requires the development of vaccineε that can protect against respiratory challenge. The induction of respiratory IgA as well as serum IgG is likely to be critically important to the εucceεs of such vaccines. To elicit effective respiratory, aε well as systemic, immunity it may be necessary to develop a vaccine system that can be delivered intranasally, aε well as parenterally.

BALB/c mice (8 animals/group) were immunized twice by intranasal slow dropwise inεtillation into both nostrils with SEB-Toxoid F (10 μg doses) formulated with or without proteosomes as a free antigen or adjuvanted with SME. Immunogenicity of these formulations was evaluated after the two immunizations by determining εyεtemic IgG antibody activity againεt SEB and induction of anti-SEB reεpiratory IgA antibody titerε. - 31 -

As shown in Table 2, Toxoid-F formulated in extrinsic SME either with or without proteosomes conferred intranasal immunogenicity resulting in 500- to 2000-fold enhancement of anti-SEB serum IgG antibody activity.

TABLE 2. Effects of formulation of formalized SEB (Toxoid-F) with submicron emulsion (SME) and/or proteosomes on induction of anti-SEB serum IgG following intranasal immunization

Figure imgf000033_0001

Extrinsic SME formation of Toxoid-F complexed to proteosomes also enhanced lung IgA antibody levels to SEB (Table 3) .

TABLE 3. Enhanced production of anti-seb respiratory (lung) IgA antibodies after intranasal immunization of BALB/c mice with 10 μg SEB-Toxoid F antigen alone or adjuvanted with SME

Figure imgf000033_0002
- 32 -

Example 14: Intranasal immunization with lipopolysaccharide (LPS) antigen from S.flex complexed to proteosomes adjuvanted with Extrinsic-SME.

Evidence that the SME has potential as a mucosal adjuvant is also shown by the ability of the extrinsic-SME adjuvant formulation to markedly enhance the lung IgA of the proteosome-LPS antigen when given intranasally (Table 4) compared to the free antigen. The immunization protocol included two groups of BALB/c mice (4 animals each) which were immunized intranasally with 10 μg does of LPS from S . flex compared to proteosomes. The non- covalent complexation of LPS to proteosomes waε carried out in a εimilar way aε deεcribed in Example 2.

TABLE 4. Induction of mucosal immunity after intranasal immunization of Balb/C mice with 10 μg LPS-complexed to proteosomes as a free antigen or adjuvanted with extrinsic-SME.

Figure imgf000034_0001

Example 15: Oral (intragastric) immunization of mice with lipopolysaccharide (LPS) antigen from S.flex complexed to proteosomes adjuvanted with extrinsic-SME.

BALB/c mice (5 animals/group) were immunized orally

(intragastrically) with 100 μg doeε of LPS complexed to proteosomes and adjuvanted with extrinsic SME. As shown in Table 5, the SME adjuvant formulation was able to induce higher anti-S.flex LPS intestinal IgA titers, compared to the free antigen. TABLE 5. Induction of mucosal immunity after oral (intragastric) immunization of Balb/C mice with LPS- complexed to proteosomes as a free antigen or adjuvanted with extrinsic-SME.

Figure imgf000035_0001

Example 16: Protection against systemic challenge with

SEB by SEB Toxoid vaccines formulated with SME adjuvant administered parenterally or intranasally

Mice immunized parenterally (Table 6) or intranasally

(Table 7) with Staphylococcus Enterotoxin B in mice immunized with SEB Toxoid-F vaccines formulated with SME or proteosomeε were significantly protected against systemic SEB challenge (100 μg toxin) .

TABLE 6. Correlation of anti-SEB serum IgG titers obtained after parenteral (i.m.) immunization (50 μg SEB- Toxoid F) with protection against systemic challenge with 100 μg SEB ion CD-l mice.

Figure imgf000035_0002
34 -

TABLE 7. Correlation of anti-SEB serum IgG titers with protection against systemic (im) challenge with 100 μg SEB in D-galactosamine-sensitized inbred (Balb/C) mice: effect of proteosomes and SME on efficacy of intranasal immunization with formalinized (Toxoid-F) SEB vaccines.

Figure imgf000036_0001

The data in Table 6 show a very good correlation between the anti-SEB serum IgG titers obtained after intramuscular immunization of CD-I mice with protection against syεtemic challenge with 100 μg of SEB. In the groupε immunized with either extrinsic or intrinsic SME- SEB Toxoid F vaccines, the survival was 100% while for animals immunized with free antigen or alum-adjuvanted vaccine the survival was 0 and 40%, respectively.

Table 7 shows similar data for BALB/c mice immunized intranasally with SEB-Toxoid F alone or complexed to proteosomes in SME adjuvant or aε free antigen.

Example 17: Enhanced murine immunogenicity of gp 160

HIV antigen incorporated in SME adjuvants either intrinsically or extrinsically. The antigens used were gp 160 alone or gp 160 complexed to meningococcal outer membrane proteosomes. These antigens were formulated with SME either intrinsically or extrinsically and compared to the gp 160 used without an adjuvant, as described in Examples 1-4. Mice (5 animals/group) were immunized three times at 3-4 week intervals. Sera, obtained after 2 and 3 immunizations were analyzed for specific anti-gp 160 peptide IgG responses by quantitative Western blot techniques using seven specific HIV epitopes aε the detecting antigenε. As εhown in Table 8a, both intrinεic and extrinsic formulations of SME were effective in enhancing immunity to several gpl60 epitopes. Note that the strongest and broadest anti-HIV responses were obtained with the intrinsic formulation uεing gp 160-proteoεomes as the antigen (rowε 5 and 11 in Table 8a) .

Example 18: Enhanced lapine immunogenicity of gpl60

HIV antigen free or complexed to proteosomes formulated in SME vaccine adjuvants.

The antigens used were gpl60 alone or gpl60 complexed to meningococcal outer membrane proteosomes. These antigens were formulated with SME either intrinsically or extrinsically and compared to gpl60-alum, gpl60- proteoεomeε, and gpl60-proteoεomeε-alum formulationε.

Rabbits (4 animals/group) were immunized parenterally four times at different intervals. Sera, obtained after second, third and fourth immunizations were analyzed by for specific anti-gpl60 peptide IgG responεeε by quantitative Eaεtern blot techniqueε uεing seven specific HIV epitopes as the detecting antigens. As shown in Table 8b, intrinsic formulations with SME with or without proteosomes were effective in enhancing immunity to several gpl60 epitopes and even gpl60 formulated with only an SEM-intrinsic preparation waε aε good aε or better than gpl60 formulated with alum, a known adjuvant currently used in people. TABLE 8a: Sub-Micron Emulsions Enhance the Immunogenicity of Proteins alone or Protein-Proteosomes Complexes in Mice

Figure imgf000038_0001

TABLE 8b: Sub-Micron Emulsions Enhance the immunogenicity of Proteins alone in Rabbits

Data From Rabbit Immunogenicity

Figure imgf000038_0002
Another analysis of the experiment showing adjuvant effects of SME with gpl60 vaccines in rabbits in which the antigens used were gpl60 alone or gpl60 complexed to meningococcal outer membrane proteosomeε iε shown in Figureε 4 and 5. Theεe antigenε were formulated with SME either intrinεically or extrinsically and compared to gpl60-alum, gpl60-proteosomeε, and gpl60-proteoεomeε-alum formulationε. Rabbitε (4 animalε per groupε) were immunized parenterally four timeε at different intervalε. Sera, obtained after second, third and fourth immunizations were analyzed by ELISA techniques using several specific HIV epitopes as the detecting antigens. As shown in Figure 4, intrinsic formulations with SME with or without proteosomeε were effective in enhancing immunity to several gpl60 epitopeε.

Among the εix groups teεted, the intrinεic-SME vaccine formulation containing the gpl60 antigen in the absence of alum, was the moεt effective vaccine eliciting the high antibody titerε with improved and extended immunogenicity against several selected gp 160 epitopes compared to the standard alum-adjuvanted vaccine actually in clinical trials.

More importantly, the SME-intrinsic formulations of gpl60 were able to induce IgG antibodies against the V3 loop epitope of the gpl60 molecule (Fig. 5 and Table 8b) , the site of the principal neutralizing determinant which blocks binding to CD4 (the main cellular receptor for HIV) . Since the standard alum-adjuvanted formulation did not generate antibodies against the V3 peptide domain, the additional epitope recognition and enhanced total immunogenicity of SME-intrinsic adjuvant is considered to be a very significant achievement. These data are encouraging for the development of enhanced εubunit formulations of gpl60 vaccines for HIV vaccine therapy.

Example 19: Immunogenicity of eishmania glycoproteins formulated in extrinsic-SME adjuvant either with or without proteosomes.

The gene for a surface protein antigen of Leiεhmania major gp63, has been cloned and sequenced. This protein, recombinantly expressed in live Salmonella, or given in a sub-unit vaccine as either the purified native gp63 or selected gp63 peptides (Jardim A., Alexander J. , Teh S.,

Ou D, Olafson R.W. 1990. J. Exp. Med. 172: 645), haε recently been shown to limit the extent to lesion development in murein models of cutaneous leishmaniasis when given with certain adjuvants. These results suggest that a vaccine to protect humans against leiεhmaniasis co poεed of defined purified componentε iε a realiεtic goal. The sub-unit vaccines were effective, however, only when adminiεtered with adjuvants containing

Corynebacterium parvum (CPV) and poloxamer 407. Other adjuvants (Complete Freund's Adjuvant, CFA), or lack of adjuvant exacerbated diseaεe.

Major εucceεε waε achieved with the discovery that subcutaneous immunization with one small gp63 peptide covalently conjugated to lauryl-cysteine protected againεt sever Leiεhmania cutaneous leεionε with reduction of lesionε in three εeparate experiments.

The objective in the present example was to demonstrate immunogenicity and efficacy of an SME-adjuvanted lipopeptide vaccine to protect againεt severe morbidity of cutaneous leishmaniasis in murein models. - 39 -

TABLE 9. Effect of immunization with LC-467 Leishmania lipopeptide formulated in SME adjuvant either with or without proteosomes on lesion size.

Figure imgf000041_0001

The antigen used were lipopeptides obtained from the major glycoprotein of the Leishmania parasite. The peptides (denoted 457 and 154) were covalently attached to lauryl cysteine to εerve aε the hydrophobic foot. The vaccine was prepared by gentle mixing of the antigens at room temperature with plain extrinsic-SME for 15 min.

Two animal models were used: (1) CBA mouse, model similar to human cutaneous disease; and (2) BALB/c mice, model similar to visceral Leiεhmania which iε lethal if not treated.

The immunization protocol included two injectionε of the animalε (8 mice/group) at weekε 0 and 3 with the experimental vaccineε (50 μg peptide/mouεe) . At week 6 the mice were infected with live Leiεhmania paraεites and the lesion size aε function of time was measured and compared. The results were expressed as % decrease from control (PBS injection) . Different vaccine formulations containing SME with or without proteosomeε were tested.

Appropriate control formulations were used.

All the formulations tested containing the 154 glycopeptide had no effect on lesion size, even if this vaccine contained proteosomes, SME or their combination. However, when the LC-467-glycopeptide was used, up to 90% decrease in lesion size was obtained by incorporation of the lipopeptide in SME, even in the absence of proteosomes (Table 8) .

Since there is considerable homology among Leiεhmania strains, this peptide may have wide application in ameliorating lesions caused by other forms of Leiεhmania .

Incorporation by reference To the extent neceεεary to underεtand or complete the disclosure of the present invention, all publications, patents, and patent applications mentioned herein are expresεly incorporated by reference therein to the same extent as though each were individually so incorporated.

Claims

THE CLAIMSWhat is claimed is:
1. A vaccine adjuvant composition of an oil-in- water submicron emulsion conεisting essentially of about 0.5 to 50% of a first component of an oil, about 0.1 to 10% of a second component of an emulsifier, about 0.05 to 5% of a non-ionic surfactant, about 0.00001 to 1% of an immunogen, and an aqueous continuous phase, said εubmicron emulεion having a mean droplet εize in the range of between about 0.03 and 0.5 μm.
2. The emulsion of claim 1 wherein the mean droplet εize iε between about 0.05 and 0.2 μm.
3. The emulsion of claim 1 wherein the first component is a medium chain triglyceride oil, a vegetable oil, or mixtures thereof.
4. The emulsion of claim 3 wherein the first component is preεent in an amount of about 1 to 20%.
5. The emulsion of claim 1 wherein the emulsifier is a phospholipid compound or a mixture of phospholipids.
6. The emulsion of claim 5 wherein said emulsifier is selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, phoεphatidic acid, sphingomyelin and cardiolipin.
7. The emulεion of claim 6 wherein the emulεifier is present in an amount of about 0.2 to 5%.
8. The emulsion of claim 1 wherein the surfactant iε selected from the group conεisting of fatty alcohols. polyethylene glycol esters of fatty acids, polyethoxylated fatty acid esters, polyethoxylated fatty alcohol ethers, polyethoxylated alkylphenyl ethers.
9. The emulsion of claim 1 wherein the surfactant iε an alkylene oxide condensate of an organic compound having one or more hydroxyl groups.
10. The emulεion of claim 9 wherein the non-ionic surfactant is present in an amount of about 0.1 to 5%.
11. The emulsion of claim 1 wherein the first component is present in an amount of about 1 to 20%, and the second component and the non-ionic surfactant are each present in an amount of about 0.1 to 2%.
12. The composition of claim 1 wherein the immunogen iε hydrophilic, lipophilic or amphiphilic.
13. The compoεition of claim 1 wherein the immunogen iε a native, recombinant or εynthetic peptide, protein or glycoprotein derived from a bacteria, viruε or parasite.
14. The composition of claim 13 wherein the antigen is the gpl60 envelope protein of the HIV virus, or a fragment thereof.
15. The composition of claim 13 wherein the antigen is the surface glycoprotein of a Leiεhmania parasite or a fragment thereof.
16. The composition of claim 15 wherein the surface glycoprotein or peptide is covalently conjugated to a hydrophobic foot.
17. The composition of claim 16 wherein the hydrophobic foot is lauryl-cysteine.
18. The composition of claim 1 wherein the immunogen iε a protein toxoid.
19. The composition of claim 18 wherein the immunogen iε Staphylococcus Enterotoxin B toxoid.
20. The composition of claim 1 wherein The immunogen is an oligosaccharide, a polysaccharide or a lipopolysaccharide.
21. The composition of claim 20 wherein the immunogen is a lipopolysaccharide from Shigella flexneri .
22. The composition of claim 1 wherein the immunogen is complexed to proteosomeε.
23. The composition of claim 1 which is essentially free of added amounts of muramyl peptides or their lipophilic derivatives.
24. A vaccine adjuvant composition of an oil-in- water submicron emulsion consiεting eεεentially of about 0.5 to 50% of a firεt component of an oil, about 0.1 to 10% of a εecond component of an emulεifier, about 0.05 to 5% of a non-ionic εurfactant, about 0.00001 to 1% of an immunogen, and an aqueouε continuouε phase, said submicron emulsion having a mean droplet size in the range of between about 0.03 and 0.5 μm, in combination with a bioadhesive or mucoadhesive macromolecule in an amount sufficient to impart adhesive properties to the vaccine.
25. The composition of claim 24 wherein the mucoadhesive macromolecule is εelected from the group conεisting of acidic naturally occurring polymers; acidic synthetically modified natural polymers; acidic nonnatural polymers; basic polymers; neutral nonnatural polymerε; and neutral naturally occurring polymers.
26. The composition of claim 25 wherein the acidic nonnatural polymer is selected from the group consisting of polymerε and copolymers containing acrylic acid units, polymers and copolymers containing ethacrylic acid units, and poly(methylvinylether/maleic anhydride) copolymers.
27. The composition of claim 25 wherein the acidic nonnatural polymer is polyacrylic acid.
28. A vaccine adjuvant composition of an oil-in- water submicron emulsion consisting esεentially of about 0.5 to 50% of a first component of an oil, about 0.1 to 10% of a second component of an emulsifier, about 0.05 to 5% of a non-ionic surfactant, about 0.00001 to 1% of an immunogen, a cryoprotectant in an amount εufficient to facilitate lyophilization of the compoεition, and an aqueouε continuouε phaεe, εaid submicron emulsion having a mean droplet size in the range of between about 0.03 and 0.5 μm.
29. The composition of claim 28 wherein the cryoprotectant iε εelected from the group conεiεting of an amino acid, an oligopeptide and polyvinylpyrrolidone.
30. A dehydrated vaccine adjuvant composition obtained by lyophilizing the composition of claim 28 or 29, whereby a submicron emulsion is generated when water iε added to the dehydrated compoεition.
31. A dehydrated vaccine adjuvant composition for administration of an immunogen, comprising a plurality of submicron particles having a hydrophobic core, the immunogen, and a surfactant, whereby a submicron emulsion is generated when water is added to the dehydrated composition.
32. A method for preparing the composition of claim 1 by an intrinsic procedure, which compriεeε adding the immunogen to the oil phase before emulsification of the water and oil phases.
33. A method for preparing the composition of claim 1 by an intrinsic procedure, which comprises adding the immunogen to the water phase before emulsification of water and oil phases.
34. A method for preparing the composition of claim 1 by an extrinsic procedure, which comprises preparing a submicron emulsion from the oil, surfactant and emulsifier componentε, and adding the immunogen externally by mixing it with the previouεly prepared submicron emulsion.
35. A vaccine adjuvant composition prepared by adding water to the dehydrated composition of claim 31 to generate a submicron emulsion which contains the immunogen therein.
36. A method for providing enhanced immunogenicity in a subject which comprises administering the composition of claim 1, 24, 28 or 35 to the subject to introduce the immunogen therein.
37. The method of claim 36 which further compriseε adminiεtering the compoεition parenterally, orally, intranasally or topically to the subject.
38. A method of achieving mucosal immunity in a subject which compriseε administering the compoεition of claims 24 to 27 to mucosal surfaces of the subject to introduce the immunogen therein.
39. The method of claim 38 which further compriseε applying the composition at least upon a portion of the vaginal, nasal, rectal or oral mucosa of the subject.
PCT/US1993/010402 1993-10-29 1993-10-29 Submicron emulsions as vaccine adjuvants WO1995011700A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US1993/010402 WO1995011700A1 (en) 1993-10-29 1993-10-29 Submicron emulsions as vaccine adjuvants

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US1993/010402 WO1995011700A1 (en) 1993-10-29 1993-10-29 Submicron emulsions as vaccine adjuvants
US08637756 US5961970A (en) 1993-10-29 1993-10-29 Submicron emulsions as vaccine adjuvants
US08677302 US5985284A (en) 1993-10-29 1996-07-09 Oral or intranasal vaccines using hydrophobic complexes having proteosomes and lipopolysaccharides
US09407327 US6803042B2 (en) 1993-10-29 1999-09-28 Oral or intranasal vaccines using hydrophobic complexes having proteosomes and lipopolysaccharides

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US08637756 Continuation US5961970A (en) 1993-10-29 1993-10-29 Submicron emulsions as vaccine adjuvants
US08673756 Continuation US5858268A (en) 1995-06-28 1996-06-27 Liquid crystal optical element, a liquid crystal display element and a projection type liquid crystal display apparatus

Publications (1)

Publication Number Publication Date
WO1995011700A1 true true WO1995011700A1 (en) 1995-05-04

Family

ID=22237117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/010402 WO1995011700A1 (en) 1993-10-29 1993-10-29 Submicron emulsions as vaccine adjuvants

Country Status (1)

Country Link
WO (1) WO1995011700A1 (en)

Cited By (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024374A1 (en) * 1995-02-06 1996-08-15 The United States Of America, As Represented By The Secretary, Department Of Agriculture Oil emulsion vaccines prepared with animal, vegetable, and synthetic oils using a mixture of nonionic surfactants
WO1997029773A1 (en) * 1996-02-13 1997-08-21 The Nisshin Oil Mills, Ltd. Vaccine-containing emulsion and vaccine-containing powder for oral administration and process for producing the same
WO1998001558A2 (en) * 1996-07-10 1998-01-15 Intellivax, Inc. Protein and peptide vaccines for inducing mucosal immunity
EP0854729A1 (en) * 1995-09-18 1998-07-29 George H. Lowell Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines
WO1998056414A1 (en) * 1997-06-11 1998-12-17 Smithkline Beecham Biologicals S.A. Oil in water vaccine compositions
WO1999009955A2 (en) * 1997-08-22 1999-03-04 Aston University Lipid-containing compositions and uses thereof
WO1999021533A2 (en) * 1997-10-24 1999-05-06 Neorx Corporation Delivery vehicles for bioactive agents and uses thereof
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
FR2776928A1 (en) * 1998-04-03 1999-10-08 Merial Sas DNA vaccines adjuvanted
WO2000000218A1 (en) * 1998-06-26 2000-01-06 Aventis Pasteur Mucosal targeting immunisation
EP0997734A1 (en) * 1998-10-29 2000-05-03 Council of Scientific and Industrial Research A composition useful for the early diagnosis of viseral leishmaniasis and a process for preparing the same
WO2000044758A1 (en) * 1999-02-01 2000-08-03 Eisai Co., Ltd. Immunological adjuvant compound
WO2000050078A1 (en) * 1999-02-26 2000-08-31 Chiron Corporation Use of bioadhesives and adjuvants for the mucosal delivery of antigens
FR2809961A1 (en) * 2000-06-09 2001-12-14 Seppic Sa Use of ethers of sugars, such as immunity adjuvant in vaccine compositions, therapeutic compositions containing them and their use as vaccines
US6423529B1 (en) 1997-12-08 2002-07-23 Council Of Scientific & Industrial Research Composition useful for the early diagnosis of visceral leishmaniasis and a process for preparing the same
US6488933B2 (en) 1995-07-05 2002-12-03 Yeda Research And Development Co. Ltd. Preparations for the treatment of T cell mediated diseases
WO2002097072A2 (en) * 2001-05-30 2002-12-05 Saechsisches Serumwerk Dresden Branch Of Smithkline Beecham Pharma Gmbh & Co. Kg Influenza vaccine composition
US6521776B2 (en) 2000-07-31 2003-02-18 Eisai Company, Limited Immunological adjuvant compounds compositions and methods of use thereof
US6534070B1 (en) 1997-11-19 2003-03-18 Schering Aktiengesellschaft Composition with azelaic acid
US6743900B2 (en) 2000-02-15 2004-06-01 Id Biomedical Corporation Of Quebec Proteosome influenza vaccine
US6777240B2 (en) * 2000-02-10 2004-08-17 Sensys Medical, Inc. Intra-serum and intra-gel for modeling human skin tissue
JP2005041883A (en) * 1999-01-29 2005-02-17 Pfizer Prod Inc Adjuvant for use in vaccine
JP2006512401A (en) * 2001-06-05 2006-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガンThe Regents of the University of Michigan Nano-emulsion vaccine
US7122372B2 (en) 2001-10-15 2006-10-17 Curetech Ltd. Peptide useful in immunomodulation
KR100711561B1 (en) * 1999-02-01 2007-04-27 에-자이가부시기가이샤 Immunological adjuvant compound
WO2008020335A2 (en) 2006-06-09 2008-02-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
US7560584B2 (en) 1999-02-01 2009-07-14 Eisai R&D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
WO2010032138A2 (en) 2008-09-18 2010-03-25 Novartis Ag Vaccine adjuvant combinations
WO2010092479A2 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with reduced amounts of squalene
WO2010092476A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
WO2010092477A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
WO2010100632A2 (en) 2009-03-06 2010-09-10 Novartis Ag Chlamydia antigens
US7833993B2 (en) 1999-02-01 2010-11-16 Eisai R&D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
WO2010133964A1 (en) 2009-05-21 2010-11-25 Novartis Ag Reverse genetics using non-endogenous pol i promoters
WO2010136896A1 (en) 2009-05-29 2010-12-02 Novartis Ag Assays for influenza virus hemagglutinins
WO2011004263A2 (en) 2009-07-07 2011-01-13 Novartis Ag Conserved escherichia coli immunogens
WO2011008974A2 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
WO2011007257A1 (en) 2009-07-16 2011-01-20 Novartis Ag Detoxified escherichia coli immunogens
WO2011012999A1 (en) 2009-07-31 2011-02-03 Novartis Ag Reverse genetics systems
WO2011030218A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
US7915238B2 (en) 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
WO2011036562A1 (en) 2009-09-28 2011-03-31 Novartis Vaccines Institute For Global Health Srl Purification of bacterial vesicles
WO2011036564A2 (en) 2009-09-28 2011-03-31 Novartis Vaccines Institute For Global Health Srl Hyperblebbing shigella strains
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
WO2011048561A1 (en) 2009-10-20 2011-04-28 Novartis Ag Diagnostic and therapeutic methods for rheumatic heart disease based upon group a streptococcus markers
WO2011048560A1 (en) 2009-10-20 2011-04-28 Novartis Ag Improved reverse genetics methods for virus rescue
WO2011058302A1 (en) 2009-11-10 2011-05-19 Guy's And St Thomas's Nhs Foundation Trust Bacteremia-associated antigen from staphylococcus aureus
WO2011080595A2 (en) 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins
US7976852B2 (en) 2005-04-26 2011-07-12 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
WO2011104632A1 (en) 2010-02-26 2011-09-01 Novartis Ag Immunogenic proteins and compositions
US20110229516A1 (en) * 2010-03-18 2011-09-22 The Clorox Company Adjuvant phase inversion concentrated nanoemulsion compositions
EP2368572A2 (en) 2005-11-04 2011-09-28 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
WO2011121576A2 (en) 2010-04-01 2011-10-06 Novartis Ag Immunogenic proteins and compositions
EP2377552A2 (en) 2005-11-04 2011-10-19 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccines with reduced amount of emulsion adjuvant
EP2377551A2 (en) 2005-11-04 2011-10-19 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted influenza vaccines including cytokine-inducing agents
EP2382987A1 (en) 2006-03-24 2011-11-02 Novartis Vaccines and Diagnostics GmbH Storage of influenza vaccines without refrigeration
EP2382988A1 (en) 2006-03-31 2011-11-02 Novartis AG Combined mucosal and parenteral immunization against HIV
WO2011145081A1 (en) 2010-05-21 2011-11-24 Novartis Ag Influenza virus reassortment method
WO2011121305A3 (en) * 2010-03-31 2011-11-24 Stabilitech Ltd. Method for preserving alum adjuvants and alum-adjuvanted vaccines
WO2011154443A1 (en) * 2010-06-10 2011-12-15 Glaxosmithkline Biologicals S.A. Novel process
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
WO2011161551A2 (en) 2010-06-11 2011-12-29 Novartis Ag Omv vaccines
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
WO2012049662A1 (en) 2010-10-15 2012-04-19 Novartis Vaccines Institute For Global Health Srl Hyperblebbing salmonella strains
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
EP2462949A2 (en) 2007-10-19 2012-06-13 Novartis AG Meningococcal vaccine formulations
EP2478916A1 (en) 2006-01-27 2012-07-25 Novartis Vaccines and Diagnostics GmbH Influenza vaccines containing hemagglutinin and matrix proteins
WO2012103361A1 (en) 2011-01-26 2012-08-02 Novartis Ag Rsv immunization regimen
EP2484377A1 (en) 2007-06-27 2012-08-08 Novartis AG Low-additive influenza vaccines
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
EP2497495A2 (en) 2006-09-11 2012-09-12 Novartis AG Making influenza virus vaccines without using eggs
EP2510947A1 (en) 2009-04-14 2012-10-17 Novartis AG Compositions for immunising against Staphylococcus aureus
EP2514437A1 (en) 2006-07-20 2012-10-24 Novartis AG Frozen stockpiling of influenza vaccines
WO2012158613A1 (en) 2011-05-13 2012-11-22 Novartis Ag Pre-fusion rsv f antigens
EP2532362A1 (en) 2006-12-06 2012-12-12 Novartis AG Vaccines including antigen from four strains of influenza virus
WO2013009564A1 (en) 2011-07-08 2013-01-17 Novartis Ag Tyrosine ligation process
EP2548895A1 (en) 2007-01-11 2013-01-23 Novartis AG Modified saccharides
WO2013038375A2 (en) 2011-09-14 2013-03-21 Novartis Ag Methods for making saccharide-protein glycoconjugates
EP2572726A1 (en) 2007-08-01 2013-03-27 Novartis AG Compositions comprising pneumococcal antigens
WO2013057715A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
WO2013068949A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
WO2013087945A2 (en) 2012-03-02 2013-06-20 Novartis Ag Influenza virus reassortment
WO2013088367A1 (en) 2011-12-12 2013-06-20 Novartis Ag Assay for influenza virus hemagglutinins
WO2013092985A1 (en) 2011-12-23 2013-06-27 Novartis Ag Stable compositions for immunising against staphylococcus aureus
EP2614835A1 (en) 2007-11-26 2013-07-17 Novartis AG Vaccination with multiple clades of H5 influenza A virus
DE202013005100U1 (en) 2013-06-05 2013-08-26 Novartis Ag Influenza virus reassortment
DE202013005130U1 (en) 2013-06-05 2013-09-10 Novartis Ag Influenza virus reassortment
WO2013132041A2 (en) 2012-03-08 2013-09-12 Novartis Ag Adjuvanted formulations of booster vaccines
WO2013182498A1 (en) 2012-06-04 2013-12-12 Novartis Ag Improved safety testing
CN101213199B (en) 2005-06-30 2013-12-18 卫材 R&D 管理有限公司 Compounds for preparing immunological adjuvant
US8623414B2 (en) 2005-05-31 2014-01-07 Malvren Cosmeceutics Limited Compositions comprising a lipid and copolymer of styrene and maleic acid
DE202006021242U1 (en) 2005-11-04 2014-01-29 Novartis Vaccines And Diagnostics S.R.L. Emulsions with free aqueous phases surfactant as an adjuvant for influenza vaccines gap
WO2014033190A1 (en) 2012-08-31 2014-03-06 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
WO2014033191A1 (en) 2012-08-31 2014-03-06 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
WO2014037472A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
WO2014053521A2 (en) 2012-10-02 2014-04-10 Novartis Ag Nonlinear saccharide conjugates
WO2014057455A2 (en) 2012-10-10 2014-04-17 Ospedale San Raffaele S.R.L. Influenza virus and type 1 diabetes
WO2014057132A1 (en) 2012-10-12 2014-04-17 Novartis Ag Non-cross-linked acellular pertussis antigens for use in combination vaccines
WO2014086732A2 (en) 2012-12-03 2014-06-12 Novartis Ag Influenza virus reassortment
WO2014095771A1 (en) 2012-12-18 2014-06-26 Novartis Ag Conjugates for protecting against diphtheria and/or tetanus
WO2014141125A2 (en) 2013-03-13 2014-09-18 Novartis Ag Influenza virus reassortment
US8877208B2 (en) 2008-05-23 2014-11-04 The Regents Of The University Of Michigan Multivalent nanoemulsion vaccines
EP2801372A2 (en) 2013-05-10 2014-11-12 Novartis AG Avoiding narcolepsy risk in influenza vaccines
WO2014195920A2 (en) 2013-06-06 2014-12-11 Novartis Ag Influenza virus reassortment
RU2541809C2 (en) * 2003-04-04 2015-02-20 Зоетис Пи ЛЛК Mucrofluidic oil-in-water emulsion and vaccine compositions
US8962026B2 (en) 2008-09-26 2015-02-24 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
WO2015068129A1 (en) 2013-11-08 2015-05-14 Novartis Ag Salmonella conjugate vaccines
EP2889042A2 (en) 2008-03-18 2015-07-01 Novartis AG Improvements in preparation of influenza virus vaccine antigens
EP2891498A1 (en) 2007-12-20 2015-07-08 Novartis AG Fermentation processes for cultivating streptococci and purification processes for obtaining CPS therefrom
US9278127B2 (en) 2006-07-17 2016-03-08 Glaxosmithkline Biologicals, Sa Influenza vaccine
EP3017826A1 (en) 2009-03-24 2016-05-11 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
WO2016207853A2 (en) 2015-06-26 2016-12-29 Seqirus UK Limited Antigenically matched influenza vaccines
US9730999B2 (en) 2005-03-23 2017-08-15 Glaxosmithkline Biologicals Sa Adjuvanted influenza virus compositions
US9764027B2 (en) 2012-09-18 2017-09-19 Glaxosmithkline Biologicals Sa Outer membrane vesicles
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
US10029007B2 (en) 2011-10-05 2018-07-24 Stabilitech Biopharma Ltd Stabilisation of polypeptides

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852155A (en) * 1971-09-02 1974-12-03 R Moore Cryopreservation of equine cell cultures
US4073743A (en) * 1975-04-17 1978-02-14 Merck & Co., Inc. Process for preparing an emulsion
US4795635A (en) * 1985-02-10 1989-01-03 Peleg Ben Ami Vaccine system
US5026543A (en) * 1987-03-17 1991-06-25 Akzo N.V. Adjuvant mixture
WO1992000081A1 (en) * 1990-06-29 1992-01-09 Chiron Corporation Vaccine compositions containing liposomes
US5185146A (en) * 1988-01-12 1993-02-09 Hoffmann-Laroche Inc. Recombinant mva vaccinia virus

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852155A (en) * 1971-09-02 1974-12-03 R Moore Cryopreservation of equine cell cultures
US4073743A (en) * 1975-04-17 1978-02-14 Merck & Co., Inc. Process for preparing an emulsion
US4795635A (en) * 1985-02-10 1989-01-03 Peleg Ben Ami Vaccine system
US5026543A (en) * 1987-03-17 1991-06-25 Akzo N.V. Adjuvant mixture
US5185146A (en) * 1988-01-12 1993-02-09 Hoffmann-Laroche Inc. Recombinant mva vaccinia virus
WO1992000081A1 (en) * 1990-06-29 1992-01-09 Chiron Corporation Vaccine compositions containing liposomes

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ANALYTICAL BIOCHEMISTRY, Volume 211, issued 15 May 1993, FRIEDE et al., "Lyophilized Liposomes as Shelf Items for the Preparation of Immunogenic Liposome-Peptide Conjugates", pages 117-122. *
BIOTECHNOLOGY THERAPEUTICS, Volume 2, Nos. 1-2, issued 1991, BARRETT et al., "Characterization of a Vaccinia-Derived Recombinant HIV-1 gp160 Candidate Vaccine and its Immunogenicity in Champanzees", pages 91-106. *
IMMUNOLOGY, Volume 72, No. 1, issued January 1991, YANG et al., "Identification and Characterization of Host-Protective T-Cell Epitopes of a Major Surface Glycoprotein (gp63) from Leishmania Major", pages 3-9. *
INFECTION AND IMMUNITY, Volume 59, No. 9, issued September 1991, ELDRIDGE et al., "Biodegradable and Biocompatible Poly(DL-Lactide-Co-Glycolide) Microspheres as an Adjuvant for Staphylococcal Enterotoxin B Toxoid Which Enhances the Level of Toxin-Neutralizing Antibodies", pages 2978-2986. *
INFECTION AND IMMUNITY, Volume 61, No. 6, issued June 1993, ORR et al., "Immunogenicity and Efficacy of Oral or Intranasal Shigella Flexneri 2a and Shigella Sonnei Proteosome-Lipopolysaccharide Vaccines in Animal Models", pages 2390-2395. *
JOURNAL OF EXPERIMENTAL MEDICINE, Volume 167, No. 2, issued February 1988, LOWELL et al., "Peptides Bound to Proteosomes via Hydrophobic Feet Become Highly Immunogenic Without Adjuvants", pages 658-663. *
JOURNAL OF IMMUNOLOGICAL METHODS, Volume 135, Nos. 1-2, issued 31 December 1990, RUEGG et al., "Preparation of Proteosome-Based Vaccines. Correlation of Immunogenicity with Physical Characteristics", pages 101-109. *
JOURNAL OF IMMUNOLOGY, Volume 140, No. 4, issued 15 February 1988, RUSSELL et al., "Effective Immunization Against Cutaneous Leishmaniasis with Defined Membrane Antigens Reconstituted Into Liposomes", pages 1274-1279. *
JOURNAL OF PHARMACY AND PHARMACOLOGY, Volume 37, No. 10, issued October 1985, MORIMOTO et al., "Enhancement of Nasal Absorption of Insulin and Calcitonin Using Polyacrylic Acid Gel", pages 134-136. *
PHARMACEUTICAL RESEARCH, Volume 9, No. 12, issued December 1992, THERMES et al., "Mucoadhesion of Copolymers and Mixtures Containing Polyacrylic Acid", pages 1563-1567. *

Cited By (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803042B2 (en) 1993-10-29 2004-10-12 U.S. Army Medical Research Materiel Command Oral or intranasal vaccines using hydrophobic complexes having proteosomes and lipopolysaccharides
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1996024374A1 (en) * 1995-02-06 1996-08-15 The United States Of America, As Represented By The Secretary, Department Of Agriculture Oil emulsion vaccines prepared with animal, vegetable, and synthetic oils using a mixture of nonionic surfactants
US5744137A (en) * 1995-02-06 1998-04-28 The United States Of America As Represented By The Secretary Of The Agriculture Oil emulsion vaccines prepared with animal, vegetable, and synthetic oils using a mixture of nonionic surfactants
US6488933B2 (en) 1995-07-05 2002-12-03 Yeda Research And Development Co. Ltd. Preparations for the treatment of T cell mediated diseases
EP0854729A1 (en) * 1995-09-18 1998-07-29 George H. Lowell Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines
EP0854729B1 (en) * 1995-09-18 2004-03-10 ID Biomedical Corporation of Quebec Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines
WO1997029773A1 (en) * 1996-02-13 1997-08-21 The Nisshin Oil Mills, Ltd. Vaccine-containing emulsion and vaccine-containing powder for oral administration and process for producing the same
WO1998001558A3 (en) * 1996-07-10 1998-05-14 Intellivax Inc Protein and peptide vaccines for inducing mucosal immunity
WO1998001558A2 (en) * 1996-07-10 1998-01-15 Intellivax, Inc. Protein and peptide vaccines for inducing mucosal immunity
WO1998056414A1 (en) * 1997-06-11 1998-12-17 Smithkline Beecham Biologicals S.A. Oil in water vaccine compositions
WO1999009955A2 (en) * 1997-08-22 1999-03-04 Aston University Lipid-containing compositions and uses thereof
US6436905B1 (en) 1997-08-22 2002-08-20 Aston University Lipid-containing compositions and uses thereof
WO1999009955A3 (en) * 1997-08-22 1999-07-08 Univ Aston Lipid-containing compositions and uses thereof
WO1999021533A3 (en) * 1997-10-24 1999-07-08 Neorx Corp Delivery vehicles for bioactive agents and uses thereof
WO1999021533A2 (en) * 1997-10-24 1999-05-06 Neorx Corporation Delivery vehicles for bioactive agents and uses thereof
US6534070B1 (en) 1997-11-19 2003-03-18 Schering Aktiengesellschaft Composition with azelaic acid
US6423529B1 (en) 1997-12-08 2002-07-23 Council Of Scientific & Industrial Research Composition useful for the early diagnosis of visceral leishmaniasis and a process for preparing the same
US7163926B1 (en) * 1998-04-03 2007-01-16 Merial Adjuvant-containing vaccines
WO1999051269A1 (en) * 1998-04-03 1999-10-14 Merial Adjuvant-containing vaccines
FR2776928A1 (en) * 1998-04-03 1999-10-08 Merial Sas DNA vaccines adjuvanted
WO2000000218A1 (en) * 1998-06-26 2000-01-06 Aventis Pasteur Mucosal targeting immunisation
EP0997734A1 (en) * 1998-10-29 2000-05-03 Council of Scientific and Industrial Research A composition useful for the early diagnosis of viseral leishmaniasis and a process for preparing the same
JP2005041883A (en) * 1999-01-29 2005-02-17 Pfizer Prod Inc Adjuvant for use in vaccine
US6290973B1 (en) 1999-02-01 2001-09-18 Eisai Co., Ltd. Immunological adjuvant compounds, compositions, and methods of use thereof
US7560584B2 (en) 1999-02-01 2009-07-14 Eisai R&D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
US7915238B2 (en) 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
KR100711561B1 (en) * 1999-02-01 2007-04-27 에-자이가부시기가이샤 Immunological adjuvant compound
US7833993B2 (en) 1999-02-01 2010-11-16 Eisai R&D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
WO2000044758A1 (en) * 1999-02-01 2000-08-03 Eisai Co., Ltd. Immunological adjuvant compound
EP1439184A1 (en) * 1999-02-01 2004-07-21 Eisai Co., Ltd. Immunological adjuvant compounds
EP2275133A1 (en) * 1999-02-26 2011-01-19 Novartis Vaccines and Diagnostics, Inc. Use of bioadhesives and adjuvants for the mucosal delivery of antigens
WO2000050078A1 (en) * 1999-02-26 2000-08-31 Chiron Corporation Use of bioadhesives and adjuvants for the mucosal delivery of antigens
US6777240B2 (en) * 2000-02-10 2004-08-17 Sensys Medical, Inc. Intra-serum and intra-gel for modeling human skin tissue
US7399840B2 (en) 2000-02-15 2008-07-15 Id Biomedical Corporation Of Quebec Proteosome influenza vaccine
US6743900B2 (en) 2000-02-15 2004-06-01 Id Biomedical Corporation Of Quebec Proteosome influenza vaccine
EP1163909A3 (en) * 2000-06-09 2002-02-06 Societe D'exploitation De Produits Pour Les Industries Chimiques-Seppic Use of sugar ethers as immunity adjuvant in vaccine compositions, therapeutic compositions containing them and their use as vaccine
FR2809961A1 (en) * 2000-06-09 2001-12-14 Seppic Sa Use of ethers of sugars, such as immunity adjuvant in vaccine compositions, therapeutic compositions containing them and their use as vaccines
EP1163909A2 (en) * 2000-06-09 2001-12-19 Societe D'exploitation De Produits Pour Les Industries Chimiques-Seppic Use of sugar ethers as immunity adjuvant in vaccine compositions, therapeutic compositions containing them and their use as vaccine
US6521776B2 (en) 2000-07-31 2003-02-18 Eisai Company, Limited Immunological adjuvant compounds compositions and methods of use thereof
WO2002097072A2 (en) * 2001-05-30 2002-12-05 Saechsisches Serumwerk Dresden Branch Of Smithkline Beecham Pharma Gmbh & Co. Kg Influenza vaccine composition
US7316813B2 (en) 2001-05-30 2008-01-08 Saechsisches Serumwerk Dresden Branch Of Smithkline Beecham Pharma Gmbh & Co Kg Influenza vaccine composition
WO2002097072A3 (en) * 2001-05-30 2003-04-24 Saechsisches Serumwerk Influenza vaccine composition
EP2039761A1 (en) * 2001-05-30 2009-03-25 Saechsisches Serumwerk Dresden Influenza vaccine composition
JP2013253086A (en) * 2001-06-05 2013-12-19 Regents Of The Univ Of Michigan Nano-emulsion vaccine
JP2006512401A (en) * 2001-06-05 2006-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガンThe Regents of the University of Michigan Nano-emulsion vaccine
JP2010195788A (en) * 2001-06-05 2010-09-09 Regents Of The Univ Of Michigan Nanoemulsion vaccines
US7745397B2 (en) 2001-10-15 2010-06-29 Curetech Ltd. Peptide useful in immunomodulation
US7329639B2 (en) 2001-10-15 2008-02-12 Curetech Ltd. Peptide useful in immunomodulation
US7122372B2 (en) 2001-10-15 2006-10-17 Curetech Ltd. Peptide useful in immunomodulation
RU2541809C2 (en) * 2003-04-04 2015-02-20 Зоетис Пи ЛЛК Mucrofluidic oil-in-water emulsion and vaccine compositions
US9730999B2 (en) 2005-03-23 2017-08-15 Glaxosmithkline Biologicals Sa Adjuvanted influenza virus compositions
US8603482B2 (en) 2005-04-26 2013-12-10 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
US7976852B2 (en) 2005-04-26 2011-07-12 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
US8623414B2 (en) 2005-05-31 2014-01-07 Malvren Cosmeceutics Limited Compositions comprising a lipid and copolymer of styrene and maleic acid
CN103012169B (en) * 2005-06-30 2016-04-20 卫材R&D管理有限公司 For the preparation of compounds immunoadjuvant
CN101213199B (en) 2005-06-30 2013-12-18 卫材 R&D 管理有限公司 Compounds for preparing immunological adjuvant
EP2377551A2 (en) 2005-11-04 2011-10-19 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted influenza vaccines including cytokine-inducing agents
EP2377552A2 (en) 2005-11-04 2011-10-19 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccines with reduced amount of emulsion adjuvant
EP2368572A2 (en) 2005-11-04 2011-09-28 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
DE202006021242U1 (en) 2005-11-04 2014-01-29 Novartis Vaccines And Diagnostics S.R.L. Emulsions with free aqueous phases surfactant as an adjuvant for influenza vaccines gap
EP2478916A1 (en) 2006-01-27 2012-07-25 Novartis Vaccines and Diagnostics GmbH Influenza vaccines containing hemagglutinin and matrix proteins
EP2382987A1 (en) 2006-03-24 2011-11-02 Novartis Vaccines and Diagnostics GmbH Storage of influenza vaccines without refrigeration
EP2382988A1 (en) 2006-03-31 2011-11-02 Novartis AG Combined mucosal and parenteral immunization against HIV
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
WO2008020335A2 (en) 2006-06-09 2008-02-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
US9278127B2 (en) 2006-07-17 2016-03-08 Glaxosmithkline Biologicals, Sa Influenza vaccine
US9943588B2 (en) 2006-07-17 2018-04-17 Glaxosmithkline Biologicals S.A. Influenza vaccine
EP2514437A1 (en) 2006-07-20 2012-10-24 Novartis AG Frozen stockpiling of influenza vaccines
EP2497495A2 (en) 2006-09-11 2012-09-12 Novartis AG Making influenza virus vaccines without using eggs
EP2532362A1 (en) 2006-12-06 2012-12-12 Novartis AG Vaccines including antigen from four strains of influenza virus
EP2679240A1 (en) 2006-12-06 2014-01-01 Novartis AG Vaccines including antigen from four strains of influenza virus
EP2548895A1 (en) 2007-01-11 2013-01-23 Novartis AG Modified saccharides
US10016495B2 (en) 2007-04-20 2018-07-10 Glaxosmithkline Biologicals S.A. Oil-in-water emulsion influenza vaccine
US9597389B2 (en) 2007-04-20 2017-03-21 Glaxosmithkline Biologicals Sa Oil-in-water emulsion influenza vaccine
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
EP2484377A1 (en) 2007-06-27 2012-08-08 Novartis AG Low-additive influenza vaccines
EP2572726A1 (en) 2007-08-01 2013-03-27 Novartis AG Compositions comprising pneumococcal antigens
EP2462949A2 (en) 2007-10-19 2012-06-13 Novartis AG Meningococcal vaccine formulations
EP2614835A1 (en) 2007-11-26 2013-07-17 Novartis AG Vaccination with multiple clades of H5 influenza A virus
EP2891498A1 (en) 2007-12-20 2015-07-08 Novartis AG Fermentation processes for cultivating streptococci and purification processes for obtaining CPS therefrom
EP2889042A2 (en) 2008-03-18 2015-07-01 Novartis AG Improvements in preparation of influenza virus vaccine antigens
US9415006B2 (en) 2008-05-23 2016-08-16 The Regents Of The University Of Michigan Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
US8877208B2 (en) 2008-05-23 2014-11-04 The Regents Of The University Of Michigan Multivalent nanoemulsion vaccines
WO2010032138A2 (en) 2008-09-18 2010-03-25 Novartis Ag Vaccine adjuvant combinations
US9259407B2 (en) 2008-09-26 2016-02-16 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US8962026B2 (en) 2008-09-26 2015-02-24 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
EP3173097A2 (en) 2009-02-10 2017-05-31 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
EP2942062A1 (en) 2009-02-10 2015-11-11 Novartis AG Influenza vaccine regimens for pandemic-associated strains
WO2010092477A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
WO2010092476A1 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccine regimens for pandemic-associated strains
WO2010092479A2 (en) 2009-02-10 2010-08-19 Novartis Ag Influenza vaccines with reduced amounts of squalene
WO2010100632A2 (en) 2009-03-06 2010-09-10 Novartis Ag Chlamydia antigens
EP3017826A1 (en) 2009-03-24 2016-05-11 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
EP2510947A1 (en) 2009-04-14 2012-10-17 Novartis AG Compositions for immunising against Staphylococcus aureus
EP3263128A2 (en) 2009-04-14 2018-01-03 GlaxoSmithKline Biologicals S.A. Compositions for immunising against staphylococcus aureus
WO2010133964A1 (en) 2009-05-21 2010-11-25 Novartis Ag Reverse genetics using non-endogenous pol i promoters
EP2573184A1 (en) 2009-05-21 2013-03-27 Novartis AG Reverse genetics using non-endogenous POL I promoters
WO2010136896A1 (en) 2009-05-29 2010-12-02 Novartis Ag Assays for influenza virus hemagglutinins
WO2011004263A2 (en) 2009-07-07 2011-01-13 Novartis Ag Conserved escherichia coli immunogens
WO2011008974A2 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
EP3178490A2 (en) 2009-07-15 2017-06-14 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
EP2837386A1 (en) 2009-07-16 2015-02-18 Novartis AG Detoxified Escherichia coli immunogens
WO2011007257A1 (en) 2009-07-16 2011-01-20 Novartis Ag Detoxified escherichia coli immunogens
WO2011012999A1 (en) 2009-07-31 2011-02-03 Novartis Ag Reverse genetics systems
WO2011030218A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
WO2011036562A1 (en) 2009-09-28 2011-03-31 Novartis Vaccines Institute For Global Health Srl Purification of bacterial vesicles
EP3279313A2 (en) 2009-09-28 2018-02-07 GlaxoSmithKline Biologicals S.A. Hyperblebbing shigella strains
WO2011036564A2 (en) 2009-09-28 2011-03-31 Novartis Vaccines Institute For Global Health Srl Hyperblebbing shigella strains
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
WO2011048561A1 (en) 2009-10-20 2011-04-28 Novartis Ag Diagnostic and therapeutic methods for rheumatic heart disease based upon group a streptococcus markers
WO2011048560A1 (en) 2009-10-20 2011-04-28 Novartis Ag Improved reverse genetics methods for virus rescue
WO2011058302A1 (en) 2009-11-10 2011-05-19 Guy's And St Thomas's Nhs Foundation Trust Bacteremia-associated antigen from staphylococcus aureus
WO2011080595A2 (en) 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins
WO2011104632A1 (en) 2010-02-26 2011-09-01 Novartis Ag Immunogenic proteins and compositions
US20110229516A1 (en) * 2010-03-18 2011-09-22 The Clorox Company Adjuvant phase inversion concentrated nanoemulsion compositions
WO2012020326A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
WO2011121305A3 (en) * 2010-03-31 2011-11-24 Stabilitech Ltd. Method for preserving alum adjuvants and alum-adjuvanted vaccines
GB2499480A (en) * 2010-03-31 2013-08-21 Stabilitech Ltd Method for preserving alum adjuvants and alum-adjuvanted vaccines
US9101607B2 (en) 2010-03-31 2015-08-11 Stabilitech Ltd. Method for preserving alum adjuvants and alum-adjuvanted vaccines
WO2011121576A2 (en) 2010-04-01 2011-10-06 Novartis Ag Immunogenic proteins and compositions
WO2011145081A1 (en) 2010-05-21 2011-11-24 Novartis Ag Influenza virus reassortment method
US9574181B2 (en) 2010-05-21 2017-02-21 Seqirus UK Limited Influenza virus reassortment method
CN102917689A (en) * 2010-06-10 2013-02-06 葛兰素史密丝克莱恩生物有限公司 Novel process
WO2011154443A1 (en) * 2010-06-10 2011-12-15 Glaxosmithkline Biologicals S.A. Novel process
WO2011161551A2 (en) 2010-06-11 2011-12-29 Novartis Ag Omv vaccines
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
WO2012049662A1 (en) 2010-10-15 2012-04-19 Novartis Vaccines Institute For Global Health Srl Hyperblebbing salmonella strains
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
WO2012103361A1 (en) 2011-01-26 2012-08-02 Novartis Ag Rsv immunization regimen
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
WO2012158613A1 (en) 2011-05-13 2012-11-22 Novartis Ag Pre-fusion rsv f antigens
EP3275892A2 (en) 2011-05-13 2018-01-31 GlaxoSmithKline Biologicals S.A. Pre-fusion rsv f antigens
WO2013009564A1 (en) 2011-07-08 2013-01-17 Novartis Ag Tyrosine ligation process
WO2013038375A2 (en) 2011-09-14 2013-03-21 Novartis Ag Methods for making saccharide-protein glycoconjugates
US10029007B2 (en) 2011-10-05 2018-07-24 Stabilitech Biopharma Ltd Stabilisation of polypeptides
WO2013057715A1 (en) 2011-10-20 2013-04-25 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
WO2013068949A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
WO2013088367A1 (en) 2011-12-12 2013-06-20 Novartis Ag Assay for influenza virus hemagglutinins
EP3023790A1 (en) 2011-12-12 2016-05-25 Novartis AG Assay for influenza virus hemagglutinins
WO2013092985A1 (en) 2011-12-23 2013-06-27 Novartis Ag Stable compositions for immunising against staphylococcus aureus
WO2013087945A2 (en) 2012-03-02 2013-06-20 Novartis Ag Influenza virus reassortment
WO2013132041A2 (en) 2012-03-08 2013-09-12 Novartis Ag Adjuvanted formulations of booster vaccines
WO2013182498A1 (en) 2012-06-04 2013-12-12 Novartis Ag Improved safety testing
WO2014033190A1 (en) 2012-08-31 2014-03-06 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
US9926344B2 (en) 2012-08-31 2018-03-27 Glaxosmithkline Biologicals Sa Stabilised proteins for immunising against Staphylococcus aureus
WO2014033191A1 (en) 2012-08-31 2014-03-06 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
US9526776B2 (en) 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
WO2014037472A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
US9764027B2 (en) 2012-09-18 2017-09-19 Glaxosmithkline Biologicals Sa Outer membrane vesicles
WO2014053521A2 (en) 2012-10-02 2014-04-10 Novartis Ag Nonlinear saccharide conjugates
WO2014057455A2 (en) 2012-10-10 2014-04-17 Ospedale San Raffaele S.R.L. Influenza virus and type 1 diabetes
WO2014057132A1 (en) 2012-10-12 2014-04-17 Novartis Ag Non-cross-linked acellular pertussis antigens for use in combination vaccines
WO2014086732A2 (en) 2012-12-03 2014-06-12 Novartis Ag Influenza virus reassortment
WO2014095771A1 (en) 2012-12-18 2014-06-26 Novartis Ag Conjugates for protecting against diphtheria and/or tetanus
WO2014141125A2 (en) 2013-03-13 2014-09-18 Novartis Ag Influenza virus reassortment
EP2801372A2 (en) 2013-05-10 2014-11-12 Novartis AG Avoiding narcolepsy risk in influenza vaccines
DE202013005100U1 (en) 2013-06-05 2013-08-26 Novartis Ag Influenza virus reassortment
DE202013005130U1 (en) 2013-06-05 2013-09-10 Novartis Ag Influenza virus reassortment
WO2014195920A2 (en) 2013-06-06 2014-12-11 Novartis Ag Influenza virus reassortment
WO2015068129A1 (en) 2013-11-08 2015-05-14 Novartis Ag Salmonella conjugate vaccines
WO2016207853A2 (en) 2015-06-26 2016-12-29 Seqirus UK Limited Antigenically matched influenza vaccines

Similar Documents

Publication Publication Date Title
Gregoriadis Immunological adjuvants: a role for liposomes
Hamdy et al. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity
Edelman Vaccine adjuvants
Byars et al. Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity
US6207185B1 (en) Method for inducing a systemic immune response to an HIV antigen
US6060082A (en) Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US7285289B2 (en) Nanoparticle vaccines
US5026543A (en) Adjuvant mixture
US4053585A (en) Immunological preparations
US5912000A (en) Chitosan induced immunopotentiation
US5910306A (en) Transdermal delivery system for antigen
Conacher et al. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes)
Demento et al. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy
US5726292A (en) Immuno-potentiating systems for preparation of immunogenic materials
Frezard Liposomes: from biophysics to the design of peptide vaccines
Alving Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants
US20030165478A1 (en) Stabilized synthetic immunogen delivery system
US5514670A (en) Submicron emulsions for delivery of peptides
Sanchez-Pescador et al. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine.
US5149529A (en) Compositions and treatment for herpes simplex
Eldridge et al. Biodegradable microspheres: vaccine delivery system for oral immunization
Allison Squalene and squalane emulsions as adjuvants
US6299884B1 (en) Adjuvant formulation comprising a submicron oil droplet emulsion
Ott et al. MF59 design and evaluation of a safe and potent adjuvant for human vaccines
Allison et al. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR BY CA CZ DE DK FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
WWE Wipo information: entry into national phase

Ref document number: 08637756

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase in:

Ref country code: CA